{"data": [{"conversation_id": "1601232587623608320", "source": "Twitter for Android", "edit_history_tweet_ids": ["1601232587623608320"], "author_id": "1294745239656202240", "id": "1601232587623608320", "entities": {"mentions": [{"start": 31, "end": 41, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 42, "end": 54, "username": "chadinabhan", "id": "2212735524"}], "urls": [{"start": 55, "end": 78, "url": "https://t.co/FHYNbdurHs", "expanded_url": "https://twitter.com/GuiperiniMD/status/1601232587623608320/photo/1", "display_url": "pic.twitter.com/FHYNbdurHs", "media_key": "3_1601232562311004161"}]}, "lang": "en", "created_at": "2022-12-09T15:09:33.000Z", "text": "The Brazilian Mob is upgraded!\n@ASkarbnik\n@chadinabhan https://t.co/FHYNbdurHs"}, {"conversation_id": "1601080847398244352", "source": "Twitter for Android", "edit_history_tweet_ids": ["1601080847398244352"], "author_id": "1294745239656202240", "id": "1601080847398244352", "entities": {"urls": [{"start": 0, "end": 23, "url": "https://t.co/AdyeY4jjLC", "expanded_url": "https://twitter.com/GuiperiniMD/status/1601080847398244352/photo/1", "display_url": "pic.twitter.com/AdyeY4jjLC", "media_key": "3_1601080826921369601"}]}, "lang": "zxx", "created_at": "2022-12-09T05:06:35.000Z", "text": "https://t.co/AdyeY4jjLC"}, {"conversation_id": "1600865250374361089", "source": "Twitter for Android", "in_reply_to_user_id": "3497730012", "edit_history_tweet_ids": ["1600896939713007616"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1600885571286548480"}], "id": "1600896939713007616", "entities": {"mentions": [{"start": 0, "end": 10, "username": "barttels2", "id": "3497730012"}, {"start": 11, "end": 26, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 27, "end": 39, "username": "chadinabhan", "id": "2212735524"}, {"start": 40, "end": 48, "username": "Nirvana", "id": "68412310"}, {"start": 49, "end": 59, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 60, "end": 66, "username": "sghmd", "id": "53395744"}, {"start": 67, "end": 79, "username": "DocsWhoRock", "id": "1266013486376726528"}, {"start": 80, "end": 89, "username": "montypal", "id": "24660850"}, {"start": 90, "end": 102, "username": "AleckAmalia", "id": "1331336294828437504"}, {"start": 103, "end": 115, "username": "DrRanaMcKay", "id": "1113559627809996801"}], "urls": [{"start": 116, "end": 139, "url": "https://t.co/DFvyKX91Ph", "expanded_url": "https://twitter.com/GuiperiniMD/status/1600896939713007616/photo/1", "display_url": "pic.twitter.com/DFvyKX91Ph", "media_key": "16_1600896923954716674"}]}, "lang": "qme", "created_at": "2022-12-08T16:55:48.000Z", "text": "@barttels2 @AaronGoodman33 @chadinabhan @Nirvana @ASkarbnik @sghmd @DocsWhoRock @montypal @AleckAmalia @DrRanaMcKay https://t.co/DFvyKX91Ph"}, {"entities": {"annotations": [{"start": 184, "end": 187, "probability": 0.8799, "type": "Other", "normalized_text": "HGBL"}, {"start": 197, "end": 208, "probability": 0.4862, "type": "Other", "normalized_text": "pathologists"}], "mentions": [{"start": 0, "end": 9, "username": "DrAEvens", "id": "719175246050410496"}]}, "conversation_id": "1600862571162394624", "source": "Twitter for Android", "in_reply_to_user_id": "719175246050410496", "edit_history_tweet_ids": ["1600884497314381824"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1600862571162394624"}], "id": "1600884497314381824", "lang": "en", "created_at": "2022-12-08T16:06:21.000Z", "text": "@DrAEvens Great review BTW.\n\nBut I dont believe we can base our decisions solely if the pathologist thinks this is a large x intermediate cells.\n\nDo you have data on % of agreement on HGBL between pathologists?"}, {"entities": {"annotations": [{"start": 77, "end": 79, "probability": 0.4146, "type": "Other", "normalized_text": "MYC"}, {"start": 82, "end": 86, "probability": 0.6277, "type": "Other", "normalized_text": "DLBCL"}, {"start": 131, "end": 133, "probability": 0.4108, "type": "Organization", "normalized_text": "MYC"}, {"start": 136, "end": 139, "probability": 0.685, "type": "Other", "normalized_text": "HGBL"}, {"start": 174, "end": 178, "probability": 0.7017, "type": "Other", "normalized_text": "DLBCL"}, {"start": 184, "end": 187, "probability": 0.7678, "type": "Other", "normalized_text": "HGBL"}], "mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 23, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 24, "end": 33, "username": "DrAEvens", "id": "719175246050410496"}]}, "conversation_id": "1600685288430268416", "source": "Twitter for Android", "in_reply_to_user_id": "2212735524", "edit_history_tweet_ids": ["1600860652951568384"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1600701514871283715"}], "id": "1600860652951568384", "lang": "en", "created_at": "2022-12-08T14:31:36.000Z", "text": "@chadinabhan @ASkarbnik @DrAEvens Just to put some \ud83d\udd25\ud83d\udd25\n\nHow come we not treat MYC+ DLBCL with alternative treatments but we do with MYC+ HGBL when the criteria for separating DLBCL and HGBL is sometimes so shaddy?"}, {"entities": {"hashtags": [{"start": 17, "end": 28, "tag": "Medtwitter"}], "annotations": [{"start": 18, "end": 27, "probability": 0.4151, "type": "Other", "normalized_text": "Medtwitter"}, {"start": 51, "end": 59, "probability": 0.9736, "type": "Place", "normalized_text": "Argentina"}, {"start": 68, "end": 76, "probability": 0.844, "type": "Organization", "normalized_text": "World Cup"}, {"start": 121, "end": 123, "probability": 0.4618, "type": "Organization", "normalized_text": "ASH"}], "mentions": [{"start": 0, "end": 12, "username": "nihardesai7", "id": "75550503"}]}, "conversation_id": "1600845527331278848", "source": "Twitter for Android", "in_reply_to_user_id": "75550503", "edit_history_tweet_ids": ["1600851165230473216"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1600845527331278848"}], "id": "1600851165230473216", "lang": "en", "created_at": "2022-12-08T13:53:54.000Z", "text": "@nihardesai7 Hey #Medtwitter\n\nBefore you cheer for Argentina in the World Cup, remember the Brazilian mob is arriving at ASH and you may not survive.\n\n\ud83e\udd23\ud83e\udd23\ud83e\udd23\ud83e\udd23\ud83e\udd23"}, {"entities": {"annotations": [{"start": 95, "end": 98, "probability": 0.6089, "type": "Other", "normalized_text": "tafa"}, {"start": 101, "end": 104, "probability": 0.6084, "type": "Other", "normalized_text": "lena"}, {"start": 107, "end": 111, "probability": 0.6959, "type": "Other", "normalized_text": "lonca"}, {"start": 114, "end": 124, "probability": 0.5674, "type": "Other", "normalized_text": "bispecifics"}, {"start": 131, "end": 134, "probability": 0.7352, "type": "Other", "normalized_text": "CarT"}, {"start": 204, "end": 208, "probability": 0.8329, "type": "Other", "normalized_text": "EPOCH"}], "mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 27, "username": "BloodAdvances", "id": "732570175162179585"}, {"start": 28, "end": 38, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 39, "end": 54, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "conversation_id": "1600467379158294528", "source": "Twitter for Android", "in_reply_to_user_id": "2212735524", "edit_history_tweet_ids": ["1600469254553317376"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1600467379158294528"}], "id": "1600469254553317376", "lang": "en", "created_at": "2022-12-07T12:36:20.000Z", "text": "@chadinabhan @BloodAdvances @ASkarbnik @AaronGoodman33 I am for now.\nI live in a place without tafa, lena, lonca, bispecifics etc.\nCarT has Just arrived.\n\nFor now, if the patient is fit, I would consider EPOCH. \n\nI have one shot."}, {"entities": {"annotations": [{"start": 27, "end": 36, "probability": 0.4862, "type": "Other", "normalized_text": "Hematology"}, {"start": 42, "end": 49, "probability": 0.3656, "type": "Other", "normalized_text": "Oncology"}], "urls": [{"start": 52, "end": 75, "url": "https://t.co/xnMRfE1HFT", "expanded_url": "https://twitter.com/PestanaRC/status/1600227764623134721", "display_url": "twitter.com/PestanaRC/stat\u2026"}]}, "conversation_id": "1600452110969032704", "source": "Twitter for Android", "edit_history_tweet_ids": ["1600452110969032704"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "quoted", "id": "1600227764623134721"}], "id": "1600452110969032704", "lang": "en", "created_at": "2022-12-07T11:28:12.000Z", "text": "Great future ahead for our Hematology and Oncology! https://t.co/xnMRfE1HFT"}, {"conversation_id": "1600142501951651840", "source": "Twitter for Android", "in_reply_to_user_id": "3012914963", "edit_history_tweet_ids": ["1600418678507347971"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1600283244255014912"}], "id": "1600418678507347971", "entities": {"mentions": [{"start": 0, "end": 15, "username": "Data_Sommelier", "id": "3012914963"}, {"start": 16, "end": 27, "username": "booksterpp", "id": "1276697665888272384"}]}, "lang": "en", "created_at": "2022-12-07T09:15:21.000Z", "text": "@Data_Sommelier @booksterpp Idem!"}, {"conversation_id": "1599065279786409985", "source": "Twitter for Android", "in_reply_to_user_id": "354168091", "edit_history_tweet_ids": ["1600162364417986570"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1600160019168649217"}], "id": "1600162364417986570", "entities": {"mentions": [{"start": 0, "end": 12, "username": "matthew_mei", "id": "354168091"}, {"start": 13, "end": 26, "username": "paulocruzphi", "id": "1913011345"}]}, "lang": "en", "created_at": "2022-12-06T16:16:51.000Z", "text": "@matthew_mei @paulocruzphi One day you will agree with me.\nIll convince you Thursday!"}, {"conversation_id": "1600149853220192258", "source": "Twitter Web App", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1600150099002216448"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1600149853220192258"}], "id": "1600150099002216448", "lang": "en", "created_at": "2022-12-06T15:28:07.000Z", "text": "This is important because it can be cost saving (should be confirmed though). \n\nMy experience is that &gt;90% of patients dont tolerate all 16 cycles of BV due to neuropathy. Good to know they will be fine."}, {"entities": {"hashtags": [{"start": 0, "end": 12, "tag": "PeriniPicks"}, {"start": 23, "end": 29, "tag": "ASH22"}], "annotations": [{"start": 1, "end": 11, "probability": 0.4253, "type": "Other", "normalized_text": "PeriniPicks"}, {"start": 24, "end": 28, "probability": 0.4265, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 95, "end": 118, "url": "https://t.co/Bub7E7K9sR", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159001.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival", "description": "Program: Oral and Poster Abstracts Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Hodgkin lymphoma, Biological therapies, Antibody Therapy, Lymphomas, Diseases, Therapies, Lymphoid Malignancies Charlotte B Wagner, PharmD 1 *, Daniel A. Ermann, MD 2, Ken Boucher, PhD 3 *, Adrienne N. Nedved, PharmD 4 *, Ivana N. Micallef, MD 5, Sanjal H Desai, MBBS 6, Haris Hatic, DO 7, Gaurav Goyal, MD 8, Erin Zacholski, PharmD 9 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159001.html"}]}, "conversation_id": "1600149853220192258", "source": "Twitter Web App", "edit_history_tweet_ids": ["1600149853220192258"], "author_id": "1294745239656202240", "id": "1600149853220192258", "lang": "en", "created_at": "2022-12-06T15:27:09.000Z", "text": "#PeriniPicks No. 5 for #ASH22\nRWD confirms the benefit of BV consolidation after ASCT in HL. \n\nhttps://t.co/Bub7E7K9sR\n\nThe real important data in this abstract is that the benefit of BV remains in patients who needed dose-reductions or didnt get all 16 cycles."}, {"entities": {"annotations": [{"start": 14, "end": 33, "probability": 0.7745, "type": "Other", "normalized_text": "Magical Mistery Tour"}], "mentions": [{"start": 0, "end": 13, "username": "paulocruzphi", "id": "1913011345"}]}, "conversation_id": "1599065279786409985", "source": "Twitter for Android", "in_reply_to_user_id": "1913011345", "edit_history_tweet_ids": ["1600100393232388096"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599065279786409985"}], "id": "1600100393232388096", "lang": "pt", "created_at": "2022-12-06T12:10:36.000Z", "text": "@paulocruzphi Magical Mistery Tour mas voc\u00eas n\u00e3o est\u00e3o prontos pra essa conversa..."}, {"conversation_id": "1599925397139099648", "source": "Twitter for Android", "in_reply_to_user_id": "354168091", "edit_history_tweet_ids": ["1600094973361266689"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599947443327893504"}], "id": "1600094973361266689", "entities": {"mentions": [{"start": 0, "end": 12, "username": "matthew_mei", "id": "354168091"}, {"start": 13, "end": 23, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 24, "end": 39, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "lang": "en", "created_at": "2022-12-06T11:49:04.000Z", "text": "@matthew_mei @ASkarbnik @AaronGoodman33 Yup! Lets meet!\nFirst beer on me!"}, {"entities": {"annotations": [{"start": 43, "end": 44, "probability": 0.5334, "type": "Other", "normalized_text": "BR"}, {"start": 57, "end": 59, "probability": 0.5822, "type": "Other", "normalized_text": "PFS"}, {"start": 273, "end": 274, "probability": 0.5458, "type": "Other", "normalized_text": "PJ"}, {"start": 281, "end": 287, "probability": 0.7827, "type": "Organization", "normalized_text": "Nirvana"}], "mentions": [{"start": 0, "end": 10, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 11, "end": 26, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 27, "end": 39, "username": "matthew_mei", "id": "354168091"}]}, "conversation_id": "1599925397139099648", "source": "Twitter for Android", "in_reply_to_user_id": "999010996034338818", "edit_history_tweet_ids": ["1599941390443479041"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599935794260869120"}], "id": "1599941390443479041", "lang": "en", "created_at": "2022-12-06T01:38:47.000Z", "text": "@ASkarbnik @AaronGoodman33 @matthew_mei So BR+i prolongs PFS in a population usually not fit for salvage and it's crap.\n\nBut in the younger, fitter patients where salvage can be done, is practice changing. Although no OS benefit seen.\n\nMakes sense (as much sense as saying PJ &gt; Nirvana)."}, {"entities": {"annotations": [{"start": 25, "end": 30, "probability": 0.6813, "type": "Person", "normalized_text": "Jessie"}], "mentions": [{"start": 0, "end": 11, "username": "Daw6Jessie", "id": "1455299166511538176"}, {"start": 12, "end": 21, "username": "ManniMD1", "id": "1269642863924609025"}]}, "conversation_id": "1599057168103538690", "source": "Twitter for Android", "in_reply_to_user_id": "1455299166511538176", "edit_history_tweet_ids": ["1599408878436765698"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599374704380620800"}], "id": "1599408878436765698", "lang": "en", "created_at": "2022-12-04T14:22:46.000Z", "text": "@Daw6Jessie @ManniMD1 Hi Jessie. Thanks for your feedback!\nReally good to see patients in the conversation!"}, {"conversation_id": "1599212887939371008", "source": "Twitter for Android", "in_reply_to_user_id": "4067920889", "edit_history_tweet_ids": ["1599229088836616193"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599212887939371008"}], "id": "1599229088836616193", "entities": {"mentions": [{"start": 0, "end": 12, "username": "HemSandoval", "id": "4067920889"}, {"start": 13, "end": 29, "username": "RockaDomicilioP", "id": "1569047557933830146"}, {"start": 30, "end": 41, "username": "marchenajr", "id": "24793170"}, {"start": 42, "end": 57, "username": "onorosaurosrex", "id": "64529857"}]}, "lang": "en", "created_at": "2022-12-04T02:28:21.000Z", "text": "@HemSandoval @RockaDomicilioP @marchenajr @onorosaurosrex The last guitar hero."}, {"entities": {"annotations": [{"start": 42, "end": 51, "probability": 0.5009, "type": "Person", "normalized_text": "Liztomania"}], "mentions": [{"start": 0, "end": 12, "username": "HemSandoval", "id": "4067920889"}, {"start": 13, "end": 29, "username": "RockaDomicilioP", "id": "1569047557933830146"}, {"start": 30, "end": 41, "username": "marchenajr", "id": "24793170"}]}, "conversation_id": "1599183740055351296", "source": "Twitter for Android", "in_reply_to_user_id": "4067920889", "edit_history_tweet_ids": ["1599187410746687488"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599183740055351296"}], "id": "1599187410746687488", "lang": "en", "created_at": "2022-12-03T23:42:44.000Z", "text": "@HemSandoval @RockaDomicilioP @marchenajr Liztomania is top 10 songs of a lifetime."}, {"conversation_id": "1598898857294802946", "source": "Twitter for Android", "in_reply_to_user_id": "788922619005403137", "edit_history_tweet_ids": ["1599173617366884352"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599173379541864448"}], "id": "1599173617366884352", "entities": {"mentions": [{"start": 0, "end": 14, "username": "BrunoBockorny", "id": "788922619005403137"}, {"start": 15, "end": 25, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 26, "end": 38, "username": "chadinabhan", "id": "2212735524"}, {"start": 39, "end": 55, "username": "RemindMe_OfThis", "id": "1067540921451986945"}]}, "lang": "en", "created_at": "2022-12-03T22:47:56.000Z", "text": "@BrunoBockorny @ASkarbnik @chadinabhan @RemindMe_OfThis in 17 days."}, {"conversation_id": "1598826846082121728", "source": "Twitter for Android", "in_reply_to_user_id": "999010996034338818", "edit_history_tweet_ids": ["1599153508259094528"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599147358167580672"}], "id": "1599153508259094528", "entities": {"mentions": [{"start": 0, "end": 10, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 11, "end": 26, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 27, "end": 39, "username": "chadinabhan", "id": "2212735524"}]}, "lang": "en", "created_at": "2022-12-03T21:28:01.000Z", "text": "@ASkarbnik @AaronGoodman33 @chadinabhan Count with me on the drums!"}, {"conversation_id": "1599057168103538690", "source": "Twitter for Android", "in_reply_to_user_id": "1302975798304014336", "edit_history_tweet_ids": ["1599124893815406592"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599122411927896064"}], "id": "1599124893815406592", "entities": {"mentions": [{"start": 0, "end": 15, "username": "MyelomaAmateur", "id": "1302975798304014336"}, {"start": 16, "end": 25, "username": "ManniMD1", "id": "1269642863924609025"}]}, "lang": "en", "created_at": "2022-12-03T19:34:19.000Z", "text": "@MyelomaAmateur @ManniMD1 Thank you so much for bringing another perspective.\n\nThat is the hardest part on trials and medicine in general: nuance."}, {"entities": {"annotations": [{"start": 125, "end": 133, "probability": 0.8537, "type": "Organization", "normalized_text": "World Cup"}], "mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "conversation_id": "1598826846082121728", "source": "Twitter Web App", "in_reply_to_user_id": "2212735524", "edit_history_tweet_ids": ["1599111133906227200"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599103860546555905"}], "id": "1599111133906227200", "lang": "en", "created_at": "2022-12-03T18:39:39.000Z", "text": "@chadinabhan @AaronGoodman33 Only if you bring the T-shirt you own me. \n\nPs.: Brazilians never get violent. Maybe during the World Cup...\ud83d\ude33"}, {"entities": {"annotations": [{"start": 86, "end": 92, "probability": 0.9222, "type": "Organization", "normalized_text": "Nirvana"}, {"start": 155, "end": 161, "probability": 0.9826, "type": "Organization", "normalized_text": "Beatles"}, {"start": 164, "end": 169, "probability": 0.8985, "type": "Organization", "normalized_text": "Eagles"}, {"start": 179, "end": 188, "probability": 0.7441, "type": "Organization", "normalized_text": "Yatch Rock"}], "mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 28, "username": "chadinabhan", "id": "2212735524"}]}, "conversation_id": "1598826846082121728", "source": "Twitter Web App", "in_reply_to_user_id": "854692626015993857", "edit_history_tweet_ids": ["1599110786210676736"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599107232825999360"}], "id": "1599110786210676736", "lang": "en", "created_at": "2022-12-03T18:38:16.000Z", "text": "@AaronGoodman33 @chadinabhan I would never say that blafesmy.\nBut I must point out my Nirvana superfan days are long gone. \nToday Im an old man, who likes Beatles, Eagles and all Yatch Rock bands..."}, {"entities": {"annotations": [{"start": 81, "end": 84, "probability": 0.643, "type": "Other", "normalized_text": "NoLa"}, {"start": 112, "end": 118, "probability": 0.4181, "type": "Organization", "normalized_text": "Nirvana"}], "mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "conversation_id": "1598826846082121728", "source": "Twitter for Android", "in_reply_to_user_id": "854692626015993857", "edit_history_tweet_ids": ["1599094706910003200"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599094082814775296"}], "id": "1599094706910003200", "lang": "en", "created_at": "2022-12-03T17:34:22.000Z", "text": "@AaronGoodman33 Relax dude.\nYou dont annoy me.\nYou can actually buy me a beer in NoLa and I will teach you some Nirvana facts."}, {"conversation_id": "1599020892016635905", "source": "Twitter for Android", "in_reply_to_user_id": "1138405094", "edit_history_tweet_ids": ["1599089815932506113"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599082188212838400"}], "id": "1599089815932506113", "entities": {"mentions": [{"start": 0, "end": 15, "username": "Amyloid_Planet", "id": "1138405094"}]}, "lang": "en", "created_at": "2022-12-03T17:14:56.000Z", "text": "@Amyloid_Planet Its always good to discuss music.\nWay better than clinical trials! \ud83d\ude05"}, {"entities": {"annotations": [{"start": 52, "end": 63, "probability": 0.6007, "type": "Person", "normalized_text": "Mothy Phyton"}], "mentions": [{"start": 0, "end": 8, "username": "Rfonsi1", "id": "146995555"}, {"start": 9, "end": 25, "username": "RahulBanerjeeMD", "id": "26399236"}]}, "conversation_id": "1598727392272748544", "source": "Twitter for Android", "in_reply_to_user_id": "146995555", "edit_history_tweet_ids": ["1599073781326438400"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599053785661575169"}], "id": "1599073781326438400", "lang": "en", "created_at": "2022-12-03T16:11:13.000Z", "text": "@Rfonsi1 @RahulBanerjeeMD It should be.\nHappened in Mothy Phyton. \ud83e\udd23"}, {"conversation_id": "1599057168103538690", "source": "Twitter for Android", "in_reply_to_user_id": "1269642863924609025", "edit_history_tweet_ids": ["1599069822280531968"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599063273055604736"}], "id": "1599069822280531968", "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "lang": "en", "created_at": "2022-12-03T15:55:29.000Z", "text": "@ManniMD1 Sorry, lost in translation here.\nDidnt mean to be rude."}, {"entities": {"annotations": [{"start": 149, "end": 155, "probability": 0.9803, "type": "Other", "normalized_text": "Twitter"}], "mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 25, "username": "ManniMD1", "id": "1269642863924609025"}]}, "conversation_id": "1599057168103538690", "source": "Twitter for Android", "in_reply_to_user_id": "854692626015993857", "edit_history_tweet_ids": ["1599069614159564800"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599068075948929024"}], "id": "1599069614159564800", "lang": "en", "created_at": "2022-12-03T15:54:39.000Z", "text": "@AaronGoodman33 @ManniMD1 That is Just lazy simplification of all the nuances in this setting.\n\nYou are a smart guy and can do better. Even for your Twitter persona, that's Just lazy."}, {"entities": {"annotations": [{"start": 37, "end": 40, "probability": 0.4949, "type": "Other", "normalized_text": "MGUS"}], "mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "conversation_id": "1599057168103538690", "source": "Twitter for Android", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1599063527037472768"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599063070243926018"}], "id": "1599063527037472768", "lang": "en", "created_at": "2022-12-03T15:30:28.000Z", "text": "@ManniMD1 Her brother (my uncle) has MGUS.\nHe is ok with Just waiting. \n\nWith this family history, I know my odds. I will tell you how I handle it if/when it happens."}, {"entities": {"annotations": [{"start": 67, "end": 69, "probability": 0.75, "type": "Other", "normalized_text": "SMM"}, {"start": 192, "end": 193, "probability": 0.7738, "type": "Other", "normalized_text": "MM"}], "mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "conversation_id": "1599057168103538690", "source": "Twitter for Android", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1599063070243926018"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599062642412306434"}], "id": "1599063070243926018", "lang": "en", "created_at": "2022-12-03T15:28:39.000Z", "text": "@ManniMD1 Just a personal history.\nMy favourite aunt has high risk SMM. She asks me constantly if all she could do is wait for the disease to evolve. She is really smart and reads a lot about MM.\n\nShe Just cant handle being passive about it."}, {"conversation_id": "1599057168103538690", "source": "Twitter for Android", "in_reply_to_user_id": "1269642863924609025", "edit_history_tweet_ids": ["1599062642412306434"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599057168103538690"}], "id": "1599062642412306434", "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "lang": "en", "created_at": "2022-12-03T15:26:57.000Z", "text": "@ManniMD1 Let me correct you.\n\n\"Should they be offered the opportunity of consenting to participate in a trial\".\n\nEnrollment is not a passive action. People are not treated without knowing the risks/possible benefits."}, {"entities": {"annotations": [{"start": 50, "end": 70, "probability": 0.346, "type": "Other", "normalized_text": "Mustard\nPolythene Pam"}, {"start": 105, "end": 107, "probability": 0.6928, "type": "Other", "normalized_text": "MMT"}], "mentions": [{"start": 0, "end": 9, "username": "fabiopss", "id": "49103828"}]}, "conversation_id": "1599020892016635905", "source": "Twitter for Android", "in_reply_to_user_id": "49103828", "edit_history_tweet_ids": ["1599052239686901760"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599045124427636737"}], "id": "1599052239686901760", "lang": "en", "created_at": "2022-12-03T14:45:37.000Z", "text": "@fabiopss Thats a Basic mistake.\nSunking.\nMean Mr Mustard\nPolythene Pam\n\nJust not enough to compare with MMT."}, {"conversation_id": "1599020892016635905", "source": "Twitter for Android", "in_reply_to_user_id": "983320272693616640", "edit_history_tweet_ids": ["1599049530493652992"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599042070999535616"}], "id": "1599049530493652992", "entities": {"mentions": [{"start": 0, "end": 16, "username": "EduardoFlavioO1", "id": "983320272693616640"}]}, "lang": "en", "created_at": "2022-12-03T14:34:51.000Z", "text": "@EduardoFlavioO1 Its a good b-side.\nBut not in the same level."}, {"entities": {"annotations": [{"start": 15, "end": 23, "probability": 0.9792, "type": "Place", "normalized_text": "San Diego"}, {"start": 36, "end": 41, "probability": 0.9795, "type": "Place", "normalized_text": "Hawaii"}], "mentions": [{"start": 0, "end": 14, "username": "Dr_AmerZeidan", "id": "1144997352148787201"}]}, "conversation_id": "1599034589938601987", "source": "Twitter for Android", "in_reply_to_user_id": "1144997352148787201", "edit_history_tweet_ids": ["1599039352734027776"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599034589938601987"}], "id": "1599039352734027776", "lang": "en", "created_at": "2022-12-03T13:54:25.000Z", "text": "@Dr_AmerZeidan San Diego instead of Hawaii and Im 100% onboard."}, {"entities": {"annotations": [{"start": 44, "end": 48, "probability": 0.7238, "type": "Other", "normalized_text": "Pisco"}], "mentions": [{"start": 0, "end": 12, "username": "iHematologo", "id": "191828708"}]}, "conversation_id": "1599020892016635905", "source": "Twitter for Android", "in_reply_to_user_id": "191828708", "edit_history_tweet_ids": ["1599038187305041920"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599025524323790849"}], "id": "1599038187305041920", "lang": "en", "created_at": "2022-12-03T13:49:47.000Z", "text": "@iHematologo I never thought chronic use of Pisco could lead to hallucinations."}, {"entities": {"annotations": [{"start": 23, "end": 25, "probability": 0.5591, "type": "Other", "normalized_text": "MMT"}, {"start": 48, "end": 54, "probability": 0.981, "type": "Organization", "normalized_text": "Beatles"}]}, "conversation_id": "1599020892016635905", "source": "Twitter for Android", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1599021117838020608"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599020892016635905"}], "id": "1599021117838020608", "lang": "en", "created_at": "2022-12-03T12:41:57.000Z", "text": "I must also point that MMT is probably the best Beatles album but you guys are not ready for this conversation."}, {"entities": {"annotations": [{"start": 66, "end": 80, "probability": 0.4935, "type": "Other", "normalized_text": "Magical Mistery"}, {"start": 128, "end": 137, "probability": 0.4947, "type": "Other", "normalized_text": "Penny Lane"}]}, "conversation_id": "1599020892016635905", "source": "Twitter for Android", "edit_history_tweet_ids": ["1599020892016635905"], "author_id": "1294745239656202240", "id": "1599020892016635905", "lang": "en", "created_at": "2022-12-03T12:41:03.000Z", "text": "What is your favourite B-side of a Record?\n\nI have no doubt it is Magical Mistery Tour:\nHello Goodbye\nStrawberry fields Forever\nPenny Lane\nBaby you're a rich Man\nAll you need is Love"}, {"conversation_id": "1598842704016076803", "source": "Twitter for Android", "edit_history_tweet_ids": ["1598842704016076803"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "quoted", "id": "1598840613561958400"}], "id": "1598842704016076803", "entities": {"urls": [{"start": 5, "end": 28, "url": "https://t.co/sLWa8MgXsO", "expanded_url": "https://twitter.com/MauMeirelles/status/1598840613561958400", "display_url": "twitter.com/MauMeirelles/s\u2026"}]}, "lang": "art", "created_at": "2022-12-03T00:53:00.000Z", "text": "\ud83e\udd23\ud83e\udd23\ud83e\udd23\ud83e\udd23 https://t.co/sLWa8MgXsO"}, {"entities": {"annotations": [{"start": 16, "end": 20, "probability": 0.6869, "type": "Person", "normalized_text": "Aaron"}, {"start": 60, "end": 66, "probability": 0.624, "type": "Other", "normalized_text": "myeloma"}], "mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "conversation_id": "1598826846082121728", "source": "Twitter for Android", "in_reply_to_user_id": "854692626015993857", "edit_history_tweet_ids": ["1598840007640305665"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1598826846082121728"}], "id": "1598840007640305665", "lang": "en", "created_at": "2022-12-03T00:42:17.000Z", "text": "@AaronGoodman33 Aaron, you have not been told.\nAn expert in myeloma posted a tread showing his opinion on that issue. And you invited yourself to the conversation.\n\nIts ok not to agree with him. Let it go."}, {"conversation_id": "1598720361964642304", "source": "Twitter for Android", "in_reply_to_user_id": "258104765", "edit_history_tweet_ids": ["1598814584902766592"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1598720361964642304"}], "id": "1598814584902766592", "entities": {"mentions": [{"start": 0, "end": 16, "username": "Gabby_Brauner27", "id": "258104765"}]}, "lang": "en", "created_at": "2022-12-02T23:01:16.000Z", "text": "@Gabby_Brauner27 Right on spot. \nThanks God.\n\nI Just didnt know it would cost my sanity... \ud83d\ude02\ud83d\ude02\ud83d\ude02"}, {"conversation_id": "1598445821682671616", "source": "Twitter for Android", "in_reply_to_user_id": "1117857169528033280", "edit_history_tweet_ids": ["1598800947387547648"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1598532074880712704"}], "id": "1598800947387547648", "entities": {"mentions": [{"start": 0, "end": 16, "username": "LeonidasPlatan1", "id": "1117857169528033280"}, {"start": 17, "end": 33, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 34, "end": 48, "username": "Dr_AmerZeidan", "id": "1144997352148787201"}, {"start": 49, "end": 65, "username": "remindmeof_this", "id": "1507446801082814497"}]}, "lang": "en", "created_at": "2022-12-02T22:07:04.000Z", "text": "@LeonidasPlatan1 @RahulBanerjeeMD @Dr_AmerZeidan @remindmeof_this in 17 days."}, {"entities": {"annotations": [{"start": 30, "end": 32, "probability": 0.6729, "type": "Other", "normalized_text": "Dac"}], "mentions": [{"start": 0, "end": 12, "username": "HemSandoval", "id": "4067920889"}]}, "conversation_id": "1598658177087717376", "source": "Twitter for Android", "in_reply_to_user_id": "4067920889", "edit_history_tweet_ids": ["1598798971203653633"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1598795246216814593"}], "id": "1598798971203653633", "lang": "en", "created_at": "2022-12-02T21:59:13.000Z", "text": "@HemSandoval No. We switch to Dac.\nWorks better actually."}, {"conversation_id": "1598728770642288640", "source": "Twitter for Android", "in_reply_to_user_id": "999010996034338818", "edit_history_tweet_ids": ["1598730356798152705"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1598729579753082881"}], "id": "1598730356798152705", "entities": {"mentions": [{"start": 0, "end": 10, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 11, "end": 23, "username": "chadinabhan", "id": "2212735524"}, {"start": 24, "end": 33, "username": "helops79", "id": "801866196127797251"}]}, "lang": "en", "created_at": "2022-12-02T17:26:34.000Z", "text": "@ASkarbnik @chadinabhan @helops79 This is definetely the craziest world cup! So many good games!"}, {"entities": {"hashtags": [{"start": 30, "end": 44, "tag": "WorldCupASH22"}], "annotations": [{"start": 31, "end": 43, "probability": 0.7682, "type": "Other", "normalized_text": "WorldCupASH22"}], "mentions": [{"start": 0, "end": 10, "username": "ASkarbnik", "id": "999010996034338818"}]}, "conversation_id": "1598663070871687169", "source": "Twitter Web App", "in_reply_to_user_id": "999010996034338818", "edit_history_tweet_ids": ["1598676400319344642"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1598663070871687169"}], "id": "1598676400319344642", "lang": "en", "created_at": "2022-12-02T13:52:10.000Z", "text": "@ASkarbnik Of course!\nThis is #WorldCupASH22. \nBrazilians will takeover EVERYTHING."}, {"entities": {"annotations": [{"start": 35, "end": 39, "probability": 0.983, "type": "Place", "normalized_text": "Chile"}], "urls": [{"start": 68, "end": 91, "url": "https://t.co/3C6bkLRKrt", "expanded_url": "https://twitter.com/LymphomaEx/status/1598662643245424640", "display_url": "twitter.com/LymphomaEx/sta\u2026"}]}, "conversation_id": "1598676232702464000", "source": "Twitter Web App", "edit_history_tweet_ids": ["1598676232702464000"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "quoted", "id": "1598662643245424640"}], "id": "1598676232702464000", "lang": "en", "created_at": "2022-12-02T13:51:30.000Z", "text": "Great meeting from my friends from Chile!\nI`ll be there, of course! https://t.co/3C6bkLRKrt"}, {"entities": {"annotations": [{"start": 40, "end": 41, "probability": 0.6123, "type": "Other", "normalized_text": "BV"}, {"start": 46, "end": 48, "probability": 0.4367, "type": "Other", "normalized_text": "CPI"}, {"start": 76, "end": 79, "probability": 0.7741, "type": "Other", "normalized_text": "PET2"}, {"start": 103, "end": 109, "probability": 0.7234, "type": "Other", "normalized_text": "BEACOPP"}]}, "conversation_id": "1598658177087717376", "source": "Twitter Web App", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1598658639887212544"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1598658177087717376"}], "id": "1598658639887212544", "lang": "en", "created_at": "2022-12-02T12:41:36.000Z", "text": "Moreover, most public systems dont have BV or CPI avaliable. Trying to cure PET2+ patients with chemo (BEACOPP) should be encouraged in our centers. \n\nI was once against escalation, but nothing as cruel reality to change our minds..."}, {"entities": {"hashtags": [{"start": 0, "end": 12, "tag": "PeriniPicks"}, {"start": 23, "end": 29, "tag": "ASH22"}], "annotations": [{"start": 1, "end": 11, "probability": 0.3816, "type": "Other", "normalized_text": "PeriniPicks"}, {"start": 24, "end": 28, "probability": 0.4323, "type": "Other", "normalized_text": "ASH22"}, {"start": 52, "end": 56, "probability": 0.4887, "type": "Other", "normalized_text": "RATHL"}, {"start": 150, "end": 153, "probability": 0.8236, "type": "Organization", "normalized_text": "LMIC"}, {"start": 168, "end": 176, "probability": 0.3347, "type": "Place", "normalized_text": "Bleomycin"}], "urls": [{"start": 122, "end": 145, "url": "https://t.co/nDl74hiBnt", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper162780.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Advanced Stage and Relapsed Hodgkin Lymphoma Hematology Disease Topics & Pathways: Research, clinical trials, Hodgkin lymphoma, Lymphomas, Clinical Research, Combination therapy, Diseases, Therapies, Lymphoid Malignancies Stefano Luminari, MD 1, Alexander Foss\u00e5, MD, PhD 2 *, Judith Trotman, FRACP 3, Daniel Molin 4 *, Francesco Annibale d'Amore, MD, DMSc 5, Gunilla Enblad,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper162780.html"}]}, "conversation_id": "1598658177087717376", "source": "Twitter Web App", "edit_history_tweet_ids": ["1598658177087717376"], "author_id": "1294745239656202240", "id": "1598658177087717376", "lang": "en", "created_at": "2022-12-02T12:39:45.000Z", "text": "#PeriniPicks No. 6 for #ASH22\n\nLong term f/u of the RATHL trial shows safety of both escalation and de-escalation in HL. \nhttps://t.co/nDl74hiBnt\n\nIn LMIC, shortage of Bleomycin is not uncommon, and being able of using only 2 cycles in 80% of patients helps us a lot."}, {"entities": {"annotations": [{"start": 17, "end": 23, "probability": 0.9824, "type": "Other", "normalized_text": "Twitter"}], "mentions": [{"start": 0, "end": 11, "username": "hematologo", "id": "120125682"}]}, "conversation_id": "1598108572206133248", "source": "Twitter for Android", "in_reply_to_user_id": "120125682", "edit_history_tweet_ids": ["1598133398367010816"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1598132337040330753"}], "id": "1598133398367010816", "lang": "en", "created_at": "2022-12-01T01:54:28.000Z", "text": "@hematologo Just Twitter in general"}, {"entities": {"annotations": [{"start": 4, "end": 18, "probability": 0.5214, "type": "Other", "normalized_text": "Dunning-Krugger"}]}, "conversation_id": "1598108572206133248", "source": "Twitter for Android", "edit_history_tweet_ids": ["1598108572206133248"], "author_id": "1294745239656202240", "id": "1598108572206133248", "lang": "en", "created_at": "2022-12-01T00:15:49.000Z", "text": "The Dunning-Krugger effect is so embarassing..."}, {"entities": {"annotations": [{"start": 21, "end": 25, "probability": 0.7425, "type": "Person", "normalized_text": "Jesus"}, {"start": 56, "end": 60, "probability": 0.4007, "type": "Person", "normalized_text": "Holly"}], "mentions": [{"start": 0, "end": 7, "username": "kek608", "id": "28980128"}, {"start": 8, "end": 20, "username": "Dr_RShatsky", "id": "1068352638499020800"}]}, "conversation_id": "1597812836633235457", "source": "Twitter for Android", "in_reply_to_user_id": "28980128", "edit_history_tweet_ids": ["1598064484722962432"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1598060931480977409"}], "id": "1598064484722962432", "lang": "en", "created_at": "2022-11-30T21:20:38.000Z", "text": "@kek608 @Dr_RShatsky Jesus is actually God himself. The Holly trinity..."}, {"entities": {"annotations": [{"start": 74, "end": 78, "probability": 0.6956, "type": "Person", "normalized_text": "Jesus"}, {"start": 81, "end": 84, "probability": 0.5944, "type": "Person", "normalized_text": "Noah"}], "mentions": [{"start": 0, "end": 12, "username": "Dr_RShatsky", "id": "1068352638499020800"}]}, "conversation_id": "1597812836633235457", "source": "Twitter for Android", "in_reply_to_user_id": "1068352638499020800", "edit_history_tweet_ids": ["1597923274088148994"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1597812836633235457"}], "id": "1597923274088148994", "lang": "en", "created_at": "2022-11-30T11:59:31.000Z", "text": "@Dr_RShatsky I usually say that God operates his miracles through others (Jesus, Noah, etc) and that I would like to participate in the patient's miracle.\n\nI know its not an accurate take on the bible but sometimes it works."}, {"entities": {"annotations": [{"start": 122, "end": 125, "probability": 0.7164, "type": "Other", "normalized_text": "Copa"}, {"start": 140, "end": 147, "probability": 0.5261, "type": "Person", "normalized_text": "PenDrive"}]}, "conversation_id": "1597704905967685634", "source": "Twitter Web App", "edit_history_tweet_ids": ["1597704905967685634"], "author_id": "1294745239656202240", "id": "1597704905967685634", "lang": "pt", "created_at": "2022-11-29T21:31:48.000Z", "text": "Eu raramente posto algo de politica aqui, mas confesso que eu to morrendo de rir do cara inventando desculpa por estar na Copa por causa de PenDrive. \n\nNao to acreditando... kkkkkkkkkkkkkkkkkkk"}, {"entities": {"annotations": [{"start": 151, "end": 155, "probability": 0.6836, "type": "Other", "normalized_text": "HSTCL"}, {"start": 229, "end": 231, "probability": 0.6268, "type": "Other", "normalized_text": "IBD"}], "mentions": [{"start": 0, "end": 16, "username": "pauliec80859931", "id": "1410748326908100631"}, {"start": 17, "end": 32, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 33, "end": 46, "username": "GomezDLeonMD", "id": "1039939970415218688"}, {"start": 47, "end": 59, "username": "matthew_mei", "id": "354168091"}, {"start": 60, "end": 72, "username": "MediHumdani", "id": "1424156964"}, {"start": 73, "end": 86, "username": "Lymphoma_Doc", "id": "1080058020"}, {"start": 87, "end": 101, "username": "BijoyTelivala", "id": "964268621655695360"}, {"start": 102, "end": 113, "username": "WolverHeme", "id": "1504670558285406208"}, {"start": 114, "end": 125, "username": "hematologo", "id": "120125682"}, {"start": 126, "end": 138, "username": "AnnaSureda5", "id": "1330231762543370241"}, {"start": 139, "end": 150, "username": "graham74GC", "id": "2239893372"}]}, "conversation_id": "1597372199731486722", "source": "Twitter for Android", "in_reply_to_user_id": "1410748326908100631", "edit_history_tweet_ids": ["1597638339435278336"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1597399075925942272"}], "id": "1597638339435278336", "lang": "en", "created_at": "2022-11-29T17:07:17.000Z", "text": "@pauliec80859931 @AaronGoodman33 @GomezDLeonMD @matthew_mei @MediHumdani @Lymphoma_Doc @BijoyTelivala @WolverHeme @hematologo @AnnaSureda5 @graham74GC HSTCL is an extremely rare lymphoma. In my small cohort of patients, none had IBD, although one had autoimmune hepatitis. \n\nIn the literature, there is a composite risk of thiopurines and Anti-TNF. I cannot give you numbers but the risk is really low."}, {"entities": {"annotations": [{"start": 214, "end": 218, "probability": 0.7094, "type": "Other", "normalized_text": "HSTCL"}, {"start": 247, "end": 251, "probability": 0.6737, "type": "Other", "normalized_text": "MEITL"}], "mentions": [{"start": 0, "end": 12, "username": "matthew_mei", "id": "354168091"}, {"start": 13, "end": 28, "username": "ajperissinotti", "id": "1042599104227041281"}, {"start": 29, "end": 42, "username": "GomezDLeonMD", "id": "1039939970415218688"}, {"start": 43, "end": 58, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 59, "end": 71, "username": "MediHumdani", "id": "1424156964"}, {"start": 72, "end": 85, "username": "Lymphoma_Doc", "id": "1080058020"}, {"start": 86, "end": 100, "username": "BijoyTelivala", "id": "964268621655695360"}, {"start": 101, "end": 112, "username": "WolverHeme", "id": "1504670558285406208"}, {"start": 113, "end": 124, "username": "hematologo", "id": "120125682"}, {"start": 125, "end": 137, "username": "AnnaSureda5", "id": "1330231762543370241"}, {"start": 138, "end": 149, "username": "graham74GC", "id": "2239893372"}, {"start": 150, "end": 163, "username": "annabrown915", "id": "825884223794008064"}, {"start": 164, "end": 179, "username": "VictoriaNachar", "id": "326455500"}]}, "conversation_id": "1597372199731486722", "source": "Twitter for Android", "in_reply_to_user_id": "354168091", "edit_history_tweet_ids": ["1597624282884231168"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1597623696805744640"}], "id": "1597624282884231168", "lang": "en", "created_at": "2022-11-29T16:11:26.000Z", "text": "@matthew_mei @ajperissinotti @GomezDLeonMD @AaronGoodman33 @MediHumdani @Lymphoma_Doc @BijoyTelivala @WolverHeme @hematologo @AnnaSureda5 @graham74GC @annabrown915 @VictoriaNachar I have never used asparaginase in HSTCL.\nI have used in refractory MEITL after 5 lines with no response."}, {"entities": {"annotations": [{"start": 35, "end": 39, "probability": 0.8861, "type": "Place", "normalized_text": "Goi\u00e1s"}, {"start": 55, "end": 63, "probability": 0.9636, "type": "Place", "normalized_text": "S\u00e3o Paulo"}, {"start": 76, "end": 89, "probability": 0.9745, "type": "Place", "normalized_text": "Rio de Janeiro"}], "mentions": [{"start": 0, "end": 16, "username": "mario_pathology", "id": "1005247473957457921"}]}, "conversation_id": "1597558791977193473", "source": "Twitter for Android", "in_reply_to_user_id": "1005247473957457921", "edit_history_tweet_ids": ["1597611637632274432"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1597610510454759424"}], "id": "1597611637632274432", "lang": "en", "created_at": "2022-11-29T15:21:11.000Z", "text": "@mario_pathology I have moved from Goi\u00e1s (3 kisses) to S\u00e3o Paulo (1 kiss).\n\nRio de Janeiro's cariocas use 2 Kisses and there is also some trouble when we meet."}, {"entities": {"hashtags": [{"start": 23, "end": 29, "tag": "ASH22"}], "annotations": [{"start": 24, "end": 28, "probability": 0.7109, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 34, "end": 57, "url": "https://t.co/8gJ8s0vwpF", "expanded_url": "https://twitter.com/xruiztru/status/1597211562355589120", "display_url": "twitter.com/xruiztru/statu\u2026"}]}, "conversation_id": "1597558791977193473", "source": "Twitter for Android", "edit_history_tweet_ids": ["1597558791977193473"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "quoted", "id": "1597211562355589120"}], "id": "1597558791977193473", "lang": "en", "created_at": "2022-11-29T11:51:11.000Z", "text": "Very important map for #ASH22\n\ud83d\ude17\ud83d\ude17\ud83d\ude17 https://t.co/8gJ8s0vwpF"}, {"entities": {"annotations": [{"start": 49, "end": 52, "probability": 0.6607, "type": "Other", "normalized_text": "ATLL"}, {"start": 196, "end": 199, "probability": 0.5816, "type": "Other", "normalized_text": "ASCT"}], "mentions": [{"start": 0, "end": 13, "username": "GELL01433166", "id": "1325890564320092160"}, {"start": 14, "end": 25, "username": "Denicasuri", "id": "938692263181471744"}, {"start": 26, "end": 36, "username": "CamiPenaO", "id": "1205814890604175366"}, {"start": 37, "end": 48, "username": "FiadLorena", "id": "1091471892618399745"}], "urls": [{"start": 264, "end": 287, "url": "https://t.co/XgXs2UtCNn", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper170332.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Clinical Outcome: Real World Studies Based on Database Analyses Hematology Disease Topics & Pathways: Research, Lymphomas, health outcomes research, Clinical Research, Diseases, aggressive lymphoma, Lymphoid Malignancies, survivorship Abdul-Hamid Bazarbachi, MD 1, Daniel K. Reef, MD 2, Hiba Narvel, MD 1 *, Riya Patel 1,3 *, Rama Al Hamed 4 *, Astha Thakkar, MBBS 5,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper170332.html"}]}, "conversation_id": "1597554949478813697", "source": "Twitter Web App", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1597555654558126083"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1597554949478813697"}], "id": "1597555654558126083", "lang": "en", "created_at": "2022-11-29T11:38:43.000Z", "text": "@GELL01433166 @Denicasuri @CamiPenaO @FiadLorena ATLL is still a terrible disease and only with international collaboration we will overcome it!\n\nAs a related abstract, a great paper showing that ASCT is futile and patients should be treated with allo directly. \n\nhttps://t.co/XgXs2UtCNn"}, {"entities": {"hashtags": [{"start": 0, "end": 12, "tag": "PeriniPicks"}, {"start": 23, "end": 29, "tag": "ASH22"}], "annotations": [{"start": 1, "end": 11, "probability": 0.4149, "type": "Other", "normalized_text": "PeriniPicks"}, {"start": 24, "end": 28, "probability": 0.4282, "type": "Other", "normalized_text": "ASH22"}, {"start": 103, "end": 106, "probability": 0.3509, "type": "Organization", "normalized_text": "ATLL"}], "mentions": [{"start": 180, "end": 193, "username": "GELL01433166", "id": "1325890564320092160"}, {"start": 194, "end": 205, "username": "Denicasuri", "id": "938692263181471744"}, {"start": 206, "end": 216, "username": "CamiPenaO", "id": "1205814890604175366"}, {"start": 217, "end": 228, "username": "FiadLorena", "id": "1091471892618399745"}], "urls": [{"start": 126, "end": 149, "url": "https://t.co/qjABXWca7t", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168334.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Rare Populations Hematology Disease Topics & Pathways: Research, adult, epidemiology, Lymphomas, elderly, Clinical Research, T Cell lymphoma, Diseases, real-world evidence, aggressive lymphoma, Lymphoid Malignancies, young adult , Study Population, Human Bryan Valcarcel, MD 1 *, Haruhiko Sano, MD 2 *, Hiroo Katsuya, MD, PhD 3 *, Atae Utsunomiya, MD 4, Maki Otsuka, MD 5 *, Masaharu Miyahara, MD 6", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168334.html"}]}, "conversation_id": "1597554949478813697", "source": "Twitter Web App", "edit_history_tweet_ids": ["1597554949478813697"], "author_id": "1294745239656202240", "id": "1597554949478813697", "lang": "en", "created_at": "2022-11-29T11:35:55.000Z", "text": "#PeriniPicks No. 7 for #ASH22 \n\nA huge international effort to evaluate how different populations with ATLL behave (n=837!): \nhttps://t.co/qjABXWca7t\n\nCongrats to all friends from @GELL01433166 @Denicasuri @CamiPenaO @FiadLorena and others! 1st oral presentation of many to come!"}, {"entities": {"annotations": [{"start": 254, "end": 261, "probability": 0.2399, "type": "Other", "normalized_text": "Anderson"}], "mentions": [{"start": 0, "end": 11, "username": "hematologo", "id": "120125682"}, {"start": 12, "end": 27, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 28, "end": 41, "username": "GomezDLeonMD", "id": "1039939970415218688"}, {"start": 42, "end": 54, "username": "matthew_mei", "id": "354168091"}, {"start": 55, "end": 67, "username": "MediHumdani", "id": "1424156964"}, {"start": 68, "end": 81, "username": "Lymphoma_Doc", "id": "1080058020"}, {"start": 82, "end": 96, "username": "BijoyTelivala", "id": "964268621655695360"}, {"start": 97, "end": 108, "username": "WolverHeme", "id": "1504670558285406208"}, {"start": 109, "end": 121, "username": "AnnaSureda5", "id": "1330231762543370241"}, {"start": 122, "end": 133, "username": "graham74GC", "id": "2239893372"}]}, "conversation_id": "1597372199731486722", "source": "Twitter for Android", "in_reply_to_user_id": "120125682", "edit_history_tweet_ids": ["1597543483992342530"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1597388580242194434"}], "id": "1597543483992342530", "lang": "en", "created_at": "2022-11-29T10:50:22.000Z", "text": "@hematologo @AaronGoodman33 @GomezDLeonMD @matthew_mei @MediHumdani @Lymphoma_Doc @BijoyTelivala @WolverHeme @AnnaSureda5 @graham74GC 5/24 patients died during or up to 1 month after therapy.\nCMV, fungal infections were common.\n\nI Wonder if anyone at MD Anderson still uses this regimen..."}, {"entities": {"annotations": [{"start": 72, "end": 75, "probability": 0.4767, "type": "Other", "normalized_text": "CarT"}], "mentions": [{"start": 0, "end": 13, "username": "GomezDLeonMD", "id": "1039939970415218688"}]}, "conversation_id": "1597223476771053570", "source": "Twitter for Android", "in_reply_to_user_id": "1039939970415218688", "edit_history_tweet_ids": ["1597531924603764736"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1597418538050125824"}], "id": "1597531924603764736", "lang": "en", "created_at": "2022-11-29T10:04:26.000Z", "text": "@GomezDLeonMD Yes, probably. Challenging though!\nWe will have a inhouse CarT program. I'll let you know how it goes..."}, {"entities": {"annotations": [{"start": 146, "end": 149, "probability": 0.6099, "type": "Other", "normalized_text": "Allo"}, {"start": 247, "end": 249, "probability": 0.5795, "type": "Other", "normalized_text": "Rtx"}, {"start": 277, "end": 286, "probability": 0.7465, "type": "Other", "normalized_text": "Belinostat"}, {"start": 345, "end": 349, "probability": 0.6493, "type": "Other", "normalized_text": "Chemo"}], "mentions": [{"start": 0, "end": 13, "username": "GomezDLeonMD", "id": "1039939970415218688"}, {"start": 14, "end": 29, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 30, "end": 42, "username": "matthew_mei", "id": "354168091"}, {"start": 43, "end": 55, "username": "MediHumdani", "id": "1424156964"}, {"start": 56, "end": 69, "username": "Lymphoma_Doc", "id": "1080058020"}, {"start": 70, "end": 84, "username": "BijoyTelivala", "id": "964268621655695360"}, {"start": 85, "end": 96, "username": "WolverHeme", "id": "1504670558285406208"}, {"start": 97, "end": 108, "username": "hematologo", "id": "120125682"}, {"start": 109, "end": 121, "username": "AnnaSureda5", "id": "1330231762543370241"}, {"start": 122, "end": 133, "username": "graham74GC", "id": "2239893372"}]}, "conversation_id": "1597372199731486722", "source": "Twitter for Android", "in_reply_to_user_id": "1039939970415218688", "edit_history_tweet_ids": ["1597377493358768128"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1597372199731486722"}], "id": "1597377493358768128", "lang": "en", "created_at": "2022-11-28T23:50:46.000Z", "text": "@GomezDLeonMD @AaronGoodman33 @matthew_mei @MediHumdani @Lymphoma_Doc @BijoyTelivala @WolverHeme @hematologo @AnnaSureda5 @graham74GC Take him to Allo directly.\nHard to treat and also hard to evaluate response.\nIf spleen too big, I could consider Rtx or further treatment with Belinostat (what I have avaliable here).\n\nIf not, Straight to allo! Chemo Just wont do it."}, {"conversation_id": "1597223476771053570", "source": "Twitter for Android", "in_reply_to_user_id": "4067920889", "edit_history_tweet_ids": ["1597273840006356992"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1597273139368427520"}], "id": "1597273840006356992", "entities": {"mentions": [{"start": 0, "end": 12, "username": "HemSandoval", "id": "4067920889"}, {"start": 13, "end": 24, "username": "hematologo", "id": "120125682"}, {"start": 25, "end": 37, "username": "iHematologo", "id": "191828708"}, {"start": 38, "end": 52, "username": "JulioChavezMD", "id": "3327918653"}, {"start": 53, "end": 63, "username": "ASkarbnik", "id": "999010996034338818"}]}, "lang": "en", "created_at": "2022-11-28T16:58:54.000Z", "text": "@HemSandoval @hematologo @iHematologo @JulioChavezMD @ASkarbnik The data supports waiting.\nOnly 1 PD.\nLets see how it goes..."}, {"conversation_id": "1597263570819239936", "source": "Twitter for Android", "edit_history_tweet_ids": ["1597263570819239936"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "quoted", "id": "1597253587293257729"}], "id": "1597263570819239936", "entities": {"urls": [{"start": 45, "end": 68, "url": "https://t.co/JubQ6W8rts", "expanded_url": "https://twitter.com/VincentRK/status/1597253587293257729", "display_url": "twitter.com/VincentRK/stat\u2026"}]}, "lang": "en", "created_at": "2022-11-28T16:18:05.000Z", "text": "I always tell my fellows exactly the same... https://t.co/JubQ6W8rts"}, {"entities": {"annotations": [{"start": 51, "end": 54, "probability": 0.6453, "type": "Organization", "normalized_text": "LMIC"}, {"start": 72, "end": 83, "probability": 0.642, "type": "Other", "normalized_text": "biespecifics"}, {"start": 124, "end": 125, "probability": 0.4731, "type": "Other", "normalized_text": "MM"}]}, "conversation_id": "1597223476771053570", "source": "Twitter Web App", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1597224002459963392"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1597223476771053570"}], "id": "1597224002459963392", "lang": "en", "created_at": "2022-11-28T13:40:51.000Z", "text": "If I had to put my money on a winning strategy for LMIC, I would choose biespecifics. \nNot only for lymphomas, but also for MM. \nEasier, off the shell, accessible to different regions/centers. \nNot a perfect Tx, and price will be an issue. \n\nLonger F/U needed, though."}, {"entities": {"hashtags": [{"start": 0, "end": 12, "tag": "PeriniPicks"}, {"start": 23, "end": 29, "tag": "ASH22"}], "annotations": [{"start": 1, "end": 11, "probability": 0.504, "type": "Other", "normalized_text": "PeriniPicks"}, {"start": 24, "end": 28, "probability": 0.5448, "type": "Other", "normalized_text": "ASH22"}, {"start": 68, "end": 71, "probability": 0.7258, "type": "Organization", "normalized_text": "LMIC"}, {"start": 168, "end": 177, "probability": 0.8875, "type": "Other", "normalized_text": "Glofitamab"}], "urls": [{"start": 244, "end": 267, "url": "https://t.co/cFssiewpDj", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper157554.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Immune Based and Targeted Therapies in Relapsed/Refractory Large B-Cell Lymphoma Hematology Disease Topics & Pathways: Biological therapies, non-Hodgkin lymphoma, Lymphomas, Bispecific Antibody Therapy, B Cell lymphoma, Diseases, aggressive lymphoma, Therapies, Lymphoid Malignancies Martin Hutchings, MD, PhD 1 *, Carmelo Carlo-Stella, MD, PhD 2, Franck Morschhauser, MD, PhD 3 *, Emmanuel", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper157554.html"}]}, "conversation_id": "1597223476771053570", "source": "Twitter Web App", "edit_history_tweet_ids": ["1597223476771053570"], "author_id": "1294745239656202240", "id": "1597223476771053570", "lang": "en", "created_at": "2022-11-28T13:38:46.000Z", "text": "#PeriniPicks No. 8 for #ASH22 \nCarTs are going to be a challenge in LMIC, including prices, logistics, burocracy. \n\nAn option seems to be bispecifics. \nAnd the data on Glofitamab looks really good, with long responses after a finite therapy: \n\nhttps://t.co/cFssiewpDj"}, {"conversation_id": "1597185209702977536", "source": "Twitter for Android", "in_reply_to_user_id": "75550503", "edit_history_tweet_ids": ["1597213002201059328"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1597185209702977536"}], "id": "1597213002201059328", "entities": {"mentions": [{"start": 0, "end": 12, "username": "nihardesai7", "id": "75550503"}]}, "lang": "en", "created_at": "2022-11-28T12:57:09.000Z", "text": "@nihardesai7 Both is not an option?"}, {"entities": {"annotations": [{"start": 67, "end": 75, "probability": 0.978, "type": "Place", "normalized_text": "Argentina"}, {"start": 142, "end": 147, "probability": 0.9176, "type": "Organization", "normalized_text": "M\u00e9xico"}], "mentions": [{"start": 0, "end": 10, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 11, "end": 23, "username": "chadinabhan", "id": "2212735524"}, {"start": 24, "end": 33, "username": "helops79", "id": "801866196127797251"}, {"start": 34, "end": 42, "username": "FIFAcom", "id": "140070953"}, {"start": 77, "end": 88, "username": "lorenafiad", "id": "1315303290"}, {"start": 89, "end": 105, "username": "AstridPavlovsky", "id": "1091694525926567937"}, {"start": 106, "end": 118, "username": "laura_korin", "id": "1207849319770021888"}, {"start": 119, "end": 131, "username": "silcugliari", "id": "1316527561166458891"}, {"start": 149, "end": 160, "username": "hematologo", "id": "120125682"}]}, "conversation_id": "1596580581072158723", "source": "Twitter for Android", "in_reply_to_user_id": "999010996034338818", "edit_history_tweet_ids": ["1596590447874699264"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1596581244594262018"}], "id": "1596590447874699264", "lang": "en", "created_at": "2022-11-26T19:43:20.000Z", "text": "@ASkarbnik @chadinabhan @helops79 @FIFAcom I have great friends in Argentina @lorenafiad @AstridPavlovsky @laura_korin @silcugliari \n\nAlso in M\u00e9xico @hematologo \n\nA tie is good enough for me!"}, {"conversation_id": "1596547644502982658", "source": "Twitter for Android", "in_reply_to_user_id": "2626263112", "edit_history_tweet_ids": ["1596553364032327683"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1596547644502982658"}], "id": "1596553364032327683", "entities": {"mentions": [{"start": 0, "end": 11, "username": "Mohty_EBMT", "id": "2626263112"}, {"start": 12, "end": 20, "username": "TheIACH", "id": "1097392264903622658"}, {"start": 21, "end": 36, "username": "ASH_hematology", "id": "84072624"}]}, "lang": "en", "created_at": "2022-11-26T17:15:59.000Z", "text": "@Mohty_EBMT @TheIACH @ASH_hematology Brazilian people are the best! \ud83c\udfb6\ud83c\udfb6\ud83c\udfb6"}, {"conversation_id": "1596218612817154048", "source": "Twitter for Android", "in_reply_to_user_id": "1265795288427446273", "edit_history_tweet_ids": ["1596502194219634688"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1596218612817154048"}], "id": "1596502194219634688", "entities": {"mentions": [{"start": 0, "end": 12, "username": "hemepathguy", "id": "1265795288427446273"}]}, "lang": "en", "created_at": "2022-11-26T13:52:39.000Z", "text": "@hemepathguy Beautiful!"}, {"conversation_id": "1596303487171981312", "source": "Twitter for Android", "in_reply_to_user_id": "4466075238", "edit_history_tweet_ids": ["1596309927764848640"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1596303487171981312"}], "id": "1596309927764848640", "entities": {"mentions": [{"start": 0, "end": 12, "username": "drjgauthier", "id": "4466075238"}]}, "lang": "en", "created_at": "2022-11-26T01:08:39.000Z", "text": "@drjgauthier Great album!\nAutumn leaves my favourite!"}, {"entities": {"hashtags": [{"start": 73, "end": 79, "tag": "ASH22"}], "annotations": [{"start": 40, "end": 45, "probability": 0.9738, "type": "Place", "normalized_text": "Brazil"}, {"start": 53, "end": 66, "probability": 0.5851, "type": "Other", "normalized_text": "World Cup Game"}, {"start": 74, "end": 78, "probability": 0.6344, "type": "Other", "normalized_text": "ASH22"}]}, "conversation_id": "1595935093423759360", "source": "Twitter for Android", "edit_history_tweet_ids": ["1595935093423759360"], "author_id": "1294745239656202240", "id": "1595935093423759360", "lang": "en", "created_at": "2022-11-25T00:19:11.000Z", "text": "There is no Life experience as being in Brazil for a World Cup Game.\n\nAt #ASH22, if you want to have a glimpse of that, join us Brazilians for a game. \n\nYou wont regret! \ud83c\udf7b"}, {"conversation_id": "1595877882613891072", "source": "Twitter for Android", "in_reply_to_user_id": "788922619005403137", "edit_history_tweet_ids": ["1595920172891652098"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1595907309125120000"}], "id": "1595920172891652098", "entities": {"mentions": [{"start": 0, "end": 14, "username": "BrunoBockorny", "id": "788922619005403137"}, {"start": 15, "end": 27, "username": "chadinabhan", "id": "2212735524"}, {"start": 28, "end": 38, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 39, "end": 48, "username": "helops79", "id": "801866196127797251"}]}, "lang": "en", "created_at": "2022-11-24T23:19:54.000Z", "text": "@BrunoBockorny @chadinabhan @ASkarbnik @helops79 What a goal!"}, {"conversation_id": "1595917323306770432", "source": "Twitter for Android", "edit_history_tweet_ids": ["1595917323306770432"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "quoted", "id": "1595874301865086976"}], "id": "1595917323306770432", "entities": {"urls": [{"start": 27, "end": 50, "url": "https://t.co/0qNqR43xzE", "expanded_url": "https://twitter.com/laura_korin/status/1595874301865086976", "display_url": "twitter.com/laura_korin/st\u2026"}]}, "lang": "en", "created_at": "2022-11-24T23:08:35.000Z", "text": "Save it to the transplant. https://t.co/0qNqR43xzE"}, {"entities": {"annotations": [{"start": 41, "end": 46, "probability": 0.8948, "type": "Place", "normalized_text": "Guinea"}, {"start": 63, "end": 67, "probability": 0.7227, "type": "Place", "normalized_text": "\u00cdndia"}, {"start": 71, "end": 76, "probability": 0.4519, "type": "Place", "normalized_text": "Guinea"}, {"start": 92, "end": 97, "probability": 0.5734, "type": "Place", "normalized_text": "Angola"}, {"start": 101, "end": 110, "probability": 0.6477, "type": "Place", "normalized_text": "Guinea Hen"}], "mentions": [{"start": 0, "end": 13, "username": "AranhaMilton", "id": "4337973868"}]}, "conversation_id": "1595722478856314882", "source": "Twitter for Android", "in_reply_to_user_id": "4337973868", "edit_history_tweet_ids": ["1595735267478052865"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1595722478856314882"}], "id": "1595735267478052865", "lang": "pt", "created_at": "2022-11-24T11:05:09.000Z", "text": "@AranhaMilton Mesma coisa acontece com a Guinea.\n\nPorquinho da \u00cdndia = Guinea Pig\nGalinha d'Angola = Guinea Hen"}, {"conversation_id": "1595431875761373184", "source": "Twitter for Android", "in_reply_to_user_id": "2739065578", "edit_history_tweet_ids": ["1595448273917067266"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1595439752941309952"}], "id": "1595448273917067266", "entities": {"mentions": [{"start": 0, "end": 14, "username": "DavidSteensma", "id": "2739065578"}, {"start": 15, "end": 25, "username": "VincentRK", "id": "24261916"}]}, "lang": "en", "created_at": "2022-11-23T16:04:45.000Z", "text": "@DavidSteensma @VincentRK It has never been about making a point.\n\nIts all about followers..."}, {"conversation_id": "1595422824755257345", "source": "Twitter for Android", "edit_history_tweet_ids": ["1595422824755257345"], "author_id": "1294745239656202240", "id": "1595422824755257345", "entities": {"urls": [{"start": 23, "end": 46, "url": "https://t.co/PYotmPvKha", "expanded_url": "https://open.spotify.com/track/5E89Izp4YhPyNShoxiOJ1u?si=wKuADjxaQKmhpLo7LLd5ag", "display_url": "open.spotify.com/track/5E89Izp4\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1595422867398737921/bfas91Uy?format=jpg&name=orig", "width": 640, "height": 629}, {"url": "https://pbs.twimg.com/news_img/1595422867398737921/bfas91Uy?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Rock & Roll Band", "description": "Boston \u00b7 Song \u00b7 1976", "unwound_url": "https://open.spotify.com/track/5E89Izp4YhPyNShoxiOJ1u?si=wKuADjxaQKmhpLo7LLd5ag"}]}, "lang": "en", "created_at": "2022-11-23T14:23:37.000Z", "text": "What an awesome song!\n\nhttps://t.co/PYotmPvKha"}, {"conversation_id": "1595405099438071808", "source": "Twitter for Android", "edit_history_tweet_ids": ["1595405099438071808"], "author_id": "1294745239656202240", "id": "1595405099438071808", "lang": "en", "created_at": "2022-11-23T13:13:11.000Z", "text": "I could never imagine people would be celebrating and pointing fingers when a drug fail.\n\nWe should always be extremely rigorous with data, but never forget we are dealing with people who could benefit from the drug. \n\nThe drug has not failed.\nWe have failed our patients."}, {"entities": {"annotations": [{"start": 11, "end": 21, "probability": 0.4956, "type": "Person", "normalized_text": "New Hodgkin"}, {"start": 25, "end": 32, "probability": 0.7225, "type": "Other", "normalized_text": "Lymphoma"}], "urls": [{"start": 35, "end": 58, "url": "https://t.co/kLrmnvIzh5", "expanded_url": "https://twitter.com/GomezDLeonMD/status/1595222027648077824", "display_url": "twitter.com/GomezDLeonMD/s\u2026"}]}, "conversation_id": "1595233205724012548", "source": "Twitter for Android", "edit_history_tweet_ids": ["1595233205724012548"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "quoted", "id": "1595222027648077824"}], "id": "1595233205724012548", "lang": "en", "created_at": "2022-11-23T01:50:08.000Z", "text": "Is ALL the New Hodgkin's Lymphoma? https://t.co/kLrmnvIzh5"}, {"conversation_id": "1595096398693007360", "source": "Twitter for Android", "in_reply_to_user_id": "1325890564320092160", "edit_history_tweet_ids": ["1595096398693007360"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "quoted", "id": "1594906917423710209"}], "id": "1595096398693007360", "entities": {"mentions": [{"start": 0, "end": 13, "username": "GELL01433166", "id": "1325890564320092160"}, {"start": 82, "end": 93, "username": "hematologo", "id": "120125682"}], "urls": [{"start": 155, "end": 178, "url": "https://t.co/Y2kMmTWILU", "expanded_url": "https://twitter.com/ManniMD1/status/1594906917423710209", "display_url": "twitter.com/ManniMD1/statu\u2026"}]}, "lang": "en", "created_at": "2022-11-22T16:46:31.000Z", "text": "@GELL01433166 is really an impressive group! Thanks for highlighting our efforts! @hematologo should definetely be interviewed to comment these abstracts. https://t.co/Y2kMmTWILU"}, {"entities": {"annotations": [{"start": 46, "end": 50, "probability": 0.531, "type": "Other", "normalized_text": "BeEAM"}, {"start": 57, "end": 60, "probability": 0.4997, "type": "Other", "normalized_text": "BEAM"}], "mentions": [{"start": 0, "end": 12, "username": "matthew_mei", "id": "354168091"}, {"start": 13, "end": 28, "username": "VexFlexPerplex", "id": "1532253631956803584"}]}, "conversation_id": "1594755753243459599", "source": "Twitter for Android", "in_reply_to_user_id": "354168091", "edit_history_tweet_ids": ["1595070088851476480"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1595063193210351617"}], "id": "1595070088851476480", "lang": "en", "created_at": "2022-11-22T15:01:58.000Z", "text": "@matthew_mei @VexFlexPerplex Would you prefer BeEAM over BEAM?"}, {"entities": {"annotations": [{"start": 16, "end": 21, "probability": 0.9787, "type": "Place", "normalized_text": "Brazil"}, {"start": 50, "end": 53, "probability": 0.6448, "type": "Organization", "normalized_text": "BCNU"}], "mentions": [{"start": 0, "end": 12, "username": "nihardesai7", "id": "75550503"}]}, "conversation_id": "1594755753243459599", "source": "Twitter for Android", "in_reply_to_user_id": "75550503", "edit_history_tweet_ids": ["1595037365936218113"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1595003322062495744"}], "id": "1595037365936218113", "lang": "en", "created_at": "2022-11-22T12:51:57.000Z", "text": "@nihardesai7 In Brazil is almost 60x the price of BCNU! \ud83e\udd74\ud83e\udd74"}, {"entities": {"annotations": [{"start": 92, "end": 101, "probability": 0.5209, "type": "Other", "normalized_text": "Unfiltered"}], "mentions": [{"start": 0, "end": 12, "username": "nihardesai7", "id": "75550503"}, {"start": 13, "end": 27, "username": "DrNikitaMehra", "id": "228012790"}, {"start": 28, "end": 40, "username": "chadinabhan", "id": "2212735524"}]}, "conversation_id": "1594907680950218752", "source": "Twitter for Android", "in_reply_to_user_id": "75550503", "edit_history_tweet_ids": ["1595000449370886149"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1594907680950218752"}], "id": "1595000449370886149", "lang": "en", "created_at": "2022-11-22T10:25:15.000Z", "text": "@nihardesai7 @DrNikitaMehra @chadinabhan Thanks!\nIt was really an honor to be in Healthcare Unfiltered!"}, {"conversation_id": "1594778203645939713", "source": "Twitter for Android", "edit_history_tweet_ids": ["1594778203645939713"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "quoted", "id": "1594398232012115970"}], "id": "1594778203645939713", "entities": {"urls": [{"start": 42, "end": 65, "url": "https://t.co/M1FTgCKgVC", "expanded_url": "https://twitter.com/eliistender10/status/1594398232012115970", "display_url": "twitter.com/eliistender10/\u2026"}]}, "lang": "en", "created_at": "2022-11-21T19:42:07.000Z", "text": "When I try to add effects to my slides... https://t.co/M1FTgCKgVC"}, {"entities": {"hashtags": [{"start": 0, "end": 12, "tag": "PeriniPicks"}], "annotations": [{"start": 1, "end": 11, "probability": 0.4682, "type": "Other", "normalized_text": "PeriniPicks"}, {"start": 45, "end": 48, "probability": 0.5109, "type": "Other", "normalized_text": "ASCT"}, {"start": 53, "end": 61, "probability": 0.4101, "type": "Other", "normalized_text": "lymphomas"}, {"start": 100, "end": 102, "probability": 0.5522, "type": "Other", "normalized_text": "ph2"}, {"start": 120, "end": 123, "probability": 0.6101, "type": "Other", "normalized_text": "BEAM"}, {"start": 127, "end": 131, "probability": 0.4469, "type": "Other", "normalized_text": "BeEAM"}, {"start": 254, "end": 257, "probability": 0.6484, "type": "Organization", "normalized_text": "LMIC"}], "urls": [{"start": 64, "end": 87, "url": "https://t.co/tbyjTdO33D", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper157917.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Lymphoma, AML, and Multiple Sclerosis Hematology Disease Topics & Pathways: Research, clinical trials, adult, Clinical Practice (Health Services and Quality), Lymphomas, non-Hodgkin lymphoma, Non-Biological therapies, Clinical Research, Chemotherapy, patient-reported outcomes, Diseases, Therapies, clinical procedures, Lymphoid Malignancies, Adverse Events, Technology and Procedures, Study", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper157917.html"}]}, "conversation_id": "1594755753243459599", "source": "Twitter Web App", "edit_history_tweet_ids": ["1594755753243459599"], "author_id": "1294745239656202240", "id": "1594755753243459599", "lang": "en", "created_at": "2022-11-21T18:12:55.000Z", "text": "#PeriniPicks No.9 - Dont add extra costs for ASCT in lymphomas.\nhttps://t.co/tbyjTdO33D\n\nRandomized ph2 trial comparing BEAM x BeEAM shows same results. A little bit more pulmonary toxicity on the BEAM arm, but not stat significant. \n\nImportant data for LMIC countries!"}, {"entities": {"annotations": [{"start": 14, "end": 19, "probability": 0.9623, "type": "Place", "normalized_text": "Brazil"}, {"start": 25, "end": 29, "probability": 0.3779, "type": "Place", "normalized_text": "LatAm"}], "urls": [{"start": 32, "end": 55, "url": "https://t.co/sVK2PVQOAp", "expanded_url": "https://twitter.com/RahulDoc2/status/1594236682194518016", "display_url": "twitter.com/RahulDoc2/stat\u2026"}]}, "conversation_id": "1594325950040252418", "source": "Twitter for Android", "edit_history_tweet_ids": ["1594325950040252418"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "quoted", "id": "1594236682194518016"}], "id": "1594325950040252418", "lang": "en", "created_at": "2022-11-20T13:45:02.000Z", "text": "Also true for Brazil and LatAm! https://t.co/sVK2PVQOAp"}, {"conversation_id": "1593959032087367681", "source": "Twitter for Android", "in_reply_to_user_id": "354168091", "edit_history_tweet_ids": ["1594081104398467072"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1594070354095329280"}], "id": "1594081104398467072", "entities": {"mentions": [{"start": 0, "end": 12, "username": "matthew_mei", "id": "354168091"}]}, "lang": "en", "created_at": "2022-11-19T21:32:06.000Z", "text": "@matthew_mei Yep.\nIt was made to be more ironic than harsh but you know translation sometimes change the meaning of things..."}, {"entities": {"annotations": [{"start": 14, "end": 20, "probability": 0.6832, "type": "Other", "normalized_text": "Tequila"}, {"start": 33, "end": 38, "probability": 0.626, "type": "Organization", "normalized_text": "Eagles"}, {"start": 77, "end": 83, "probability": 0.9399, "type": "Other", "normalized_text": "Twitter"}, {"start": 104, "end": 113, "probability": 0.8982, "type": "Person", "normalized_text": "Nelson Ned"}], "mentions": [{"start": 130, "end": 146, "username": "andre_barcinski", "id": "1270700702608867330"}], "urls": [{"start": 147, "end": 170, "url": "https://t.co/LhOU77qJ2O", "expanded_url": "https://twitter.com/andre_barcinski/status/1593976351568134144", "display_url": "twitter.com/andre_barcinsk\u2026"}]}, "conversation_id": "1593986663054704640", "source": "Twitter for Android", "edit_history_tweet_ids": ["1593986663054704640"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "quoted", "id": "1593976351568134144"}], "id": "1593986663054704640", "lang": "pt", "created_at": "2022-11-19T15:16:49.000Z", "text": "Mesma vibe de Tequila Sunrise do Eagles. \nMUSICAO!\n\nPs.: pra isso que existe Twitter. Eu jamais ouviria Nelson Ned se n\u00e3o fosse o @andre_barcinski https://t.co/LhOU77qJ2O"}, {"conversation_id": "1593959032087367681", "source": "Twitter for Android", "edit_history_tweet_ids": ["1593959032087367681"], "author_id": "1294745239656202240", "id": "1593959032087367681", "lang": "en", "created_at": "2022-11-19T13:27:02.000Z", "text": "Just heard right now on a session:\n\n\"Transplant is a therapy for diseases without good therapy\".\n\n\ud83d\ude05\ud83d\ude05\ud83d\ude05\ud83d\ude05"}, {"entities": {"annotations": [{"start": 21, "end": 27, "probability": 0.5695, "type": "Other", "normalized_text": "Atchung"}, {"start": 31, "end": 37, "probability": 0.6517, "type": "Other", "normalized_text": "Espirro"}], "mentions": [{"start": 0, "end": 8, "username": "jlbraga", "id": "24367340"}, {"start": 9, "end": 20, "username": "tecomedina", "id": "318757188"}]}, "conversation_id": "1593688182855303171", "source": "Twitter for Android", "in_reply_to_user_id": "24367340", "edit_history_tweet_ids": ["1593743927940628486"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1593733267257233412"}], "id": "1593743927940628486", "lang": "pt", "created_at": "2022-11-18T23:12:17.000Z", "text": "@jlbraga @tecomedina Atchung e Espirro \u00e9 melhor."}, {"entities": {"annotations": [{"start": 13, "end": 18, "probability": 0.9661, "type": "Place", "normalized_text": "Brazil"}], "mentions": [{"start": 0, "end": 12, "username": "silcugliari", "id": "1316527561166458891"}]}, "conversation_id": "1593619905412300804", "source": "Twitter for Android", "in_reply_to_user_id": "1316527561166458891", "edit_history_tweet_ids": ["1593723204572512257"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1593718527546253313"}], "id": "1593723204572512257", "lang": "en", "created_at": "2022-11-18T21:49:56.000Z", "text": "@silcugliari Brazil!"}, {"conversation_id": "1593609887745036294", "source": "Twitter for Android", "in_reply_to_user_id": "999010996034338818", "edit_history_tweet_ids": ["1593627166108942343"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1593623066164109313"}], "id": "1593627166108942343", "entities": {"mentions": [{"start": 0, "end": 10, "username": "ASkarbnik", "id": "999010996034338818"}]}, "lang": "en", "created_at": "2022-11-18T15:28:19.000Z", "text": "@ASkarbnik Not at 11 am.\nUnfortunately."}, {"conversation_id": "1593619905412300804", "source": "Twitter for Android", "in_reply_to_user_id": "300938004", "edit_history_tweet_ids": ["1593627038220308480"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1593621230380367879"}], "id": "1593627038220308480", "entities": {"mentions": [{"start": 0, "end": 8, "username": "lbtrier", "id": "300938004"}]}, "lang": "en", "created_at": "2022-11-18T15:27:48.000Z", "text": "@lbtrier A lot!"}, {"entities": {"annotations": [{"start": 36, "end": 40, "probability": 0.7605, "type": "Other", "normalized_text": "DLBCL"}, {"start": 146, "end": 149, "probability": 0.8025, "type": "Organization", "normalized_text": "LMIC"}]}, "conversation_id": "1593619905412300804", "source": "Twitter Web App", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1593620627331637248"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1593620336918122497"}], "id": "1593620627331637248", "lang": "en", "created_at": "2022-11-18T15:02:20.000Z", "text": "Great data showing that at least in DLBCL, we are close to reality in Clinical trials. \n\nSo lets criticize less and do more trials!\nEspecially in LMIC, please!"}, {"entities": {"hashtags": [{"start": 0, "end": 12, "tag": "PeriniPicks"}], "annotations": [{"start": 119, "end": 123, "probability": 0.5876, "type": "Other", "normalized_text": "DLBCL"}, {"start": 190, "end": 194, "probability": 0.421, "type": "Other", "normalized_text": "DLBCL"}, {"start": 239, "end": 243, "probability": 0.5273, "type": "Other", "normalized_text": "DLBCL"}]}, "conversation_id": "1593619905412300804", "source": "Twitter Web App", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1593620336918122497"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1593619905412300804"}], "id": "1593620336918122497", "lang": "en", "created_at": "2022-11-18T15:01:11.000Z", "text": "#PeriniPicks No. 10\nAbst 1639\nHow Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?\n\nGreat work showing that control arms of ND DLBCL studies have similar outcomes of real-life DLBCL that fullfill IC/EC of these trials"}, {"entities": {"hashtags": [{"start": 64, "end": 76, "tag": "PeriniPicks"}, {"start": 81, "end": 87, "tag": "ASH22"}], "annotations": [{"start": 31, "end": 39, "probability": 0.7314, "type": "Organization", "normalized_text": "World Cup"}, {"start": 65, "end": 75, "probability": 0.6901, "type": "Other", "normalized_text": "PeriniPicks"}, {"start": 82, "end": 86, "probability": 0.7129, "type": "Other", "normalized_text": "ASH22"}, {"start": 89, "end": 96, "probability": 0.8305, "type": "Other", "normalized_text": "Lymphoma"}, {"start": 141, "end": 144, "probability": 0.7201, "type": "Organization", "normalized_text": "LMIC"}]}, "conversation_id": "1593619905412300804", "source": "Twitter Web App", "edit_history_tweet_ids": ["1593619905412300804"], "author_id": "1294745239656202240", "id": "1593619905412300804", "lang": "en", "created_at": "2022-11-18T14:59:28.000Z", "text": "Ok, let's start it because the World Cup is almost starting...\n\n#PeriniPicks for #ASH22! Lymphoma Abstracts focusing on impact of therapy in LMIC. No fancy drugs, no crazy stuff."}, {"entities": {"hashtags": [{"start": 69, "end": 81, "tag": "PeriniPicks"}], "annotations": [{"start": 43, "end": 50, "probability": 0.5444, "type": "Other", "normalized_text": "lymphoma"}, {"start": 70, "end": 80, "probability": 0.8148, "type": "Other", "normalized_text": "PeriniPicks"}], "mentions": [{"start": 0, "end": 10, "username": "ASkarbnik", "id": "999010996034338818"}]}, "conversation_id": "1593609887745036294", "source": "Twitter Web App", "in_reply_to_user_id": "999010996034338818", "edit_history_tweet_ids": ["1593617857132331009"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1593615932882042884"}], "id": "1593617857132331009", "lang": "en", "created_at": "2022-11-18T14:51:19.000Z", "text": "@ASkarbnik Just finished going through all lymphoma abstracts for my #PeriniPicks. \n\nOverdose of abstracts leads to stupid searches."}, {"conversation_id": "1593609887745036294", "source": "Twitter Web App", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1593611960909701122"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1593609887745036294"}], "id": "1593611960909701122", "lang": "en", "created_at": "2022-11-18T14:27:54.000Z", "text": "What does that mean?\n\nProbably Nothing."}, {"entities": {"hashtags": [{"start": 16, "end": 22, "tag": "ASH22"}]}, "conversation_id": "1593609887745036294", "source": "Twitter for Android", "edit_history_tweet_ids": ["1593609887745036294"], "author_id": "1294745239656202240", "id": "1593609887745036294", "lang": "in", "created_at": "2022-11-18T14:19:39.000Z", "text": "BTKi matches in #ASH22 abstracts\n\nIbrutinib - 212 \ud83c\udfc6 \nAcalabrutinib - 75\nZanubrutinib - 45\nPirtobrutinib - 17\nNemtabrutinib - 3"}, {"entities": {"annotations": [{"start": 106, "end": 115, "probability": 0.6933, "type": "Other", "normalized_text": "cytarabine"}], "mentions": [{"start": 0, "end": 12, "username": "HemSandoval", "id": "4067920889"}, {"start": 13, "end": 24, "username": "hematologo", "id": "120125682"}, {"start": 25, "end": 35, "username": "rajuan_27", "id": "85214471"}, {"start": 36, "end": 47, "username": "graham74GC", "id": "2239893372"}, {"start": 48, "end": 57, "username": "PerlaRcp", "id": "2308986078"}]}, "conversation_id": "1593352956665102336", "source": "Twitter Web App", "in_reply_to_user_id": "4067920889", "edit_history_tweet_ids": ["1593589072211202048"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1593408666832715776"}], "id": "1593589072211202048", "lang": "en", "created_at": "2022-11-18T12:56:56.000Z", "text": "@HemSandoval @hematologo @rajuan_27 @graham74GC @PerlaRcp I believe the dose is too high for subcutaneous cytarabine, isnt it?"}, {"entities": {"annotations": [{"start": 49, "end": 58, "probability": 0.6828, "type": "Other", "normalized_text": "cytarabine"}], "mentions": [{"start": 0, "end": 10, "username": "rajuan_27", "id": "85214471"}, {"start": 11, "end": 22, "username": "graham74GC", "id": "2239893372"}, {"start": 23, "end": 34, "username": "hematologo", "id": "120125682"}, {"start": 35, "end": 44, "username": "PerlaRcp", "id": "2308986078"}]}, "conversation_id": "1593352956665102336", "source": "Twitter for Android", "in_reply_to_user_id": "85214471", "edit_history_tweet_ids": ["1593358969396928513"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1593352956665102336"}], "id": "1593358969396928513", "lang": "en", "created_at": "2022-11-17T21:42:36.000Z", "text": "@rajuan_27 @graham74GC @hematologo @PerlaRcp Add cytarabine if fit enough..."}], "includes": {"users": [{"id": "1294745239656202240", "name": "Guilherme Perini, MD", "username": "GuiperiniMD"}, {"id": "3497730012", "name": "barttels", "username": "barttels2"}, {"id": "719175246050410496", "name": "Andrew M. Evens, DO, MBA, MSc", "username": "DrAEvens"}, {"id": "2212735524", "name": "chadi nabhan MD, MBA, FACP", "username": "chadinabhan"}, {"id": "75550503", "name": "\ud835\udde1\ud835\uddf6\ud835\uddf5\ud835\uddee\ud835\uddff \ud835\uddd7\ud835\uddf2\ud835\ude00\ud835\uddee\ud835\uddf6", "username": "nihardesai7"}, {"id": "3012914963", "name": "Leticia Pozza", "username": "Data_Sommelier"}, {"id": "354168091", "name": "Matthew Mei", "username": "matthew_mei"}, {"id": "1913011345", "name": "Paulo Cruz", "username": "paulocruzphi"}, {"id": "999010996034338818", "name": "Alan Skarbnik", "username": "ASkarbnik"}, {"id": "1455299166511538176", "name": "Jessie Daw, Ph.D. (she/her)", "username": "Daw6Jessie"}, {"id": "4067920889", "name": "Jose Sandoval S, MD FACP \ud83c\udde8\ud83c\uddf4\ud83c\udde8\ud83c\uddf4", "username": "HemSandoval"}, {"id": "788922619005403137", "name": "Bruno Bockorny MD FACP", "username": "BrunoBockorny"}, {"id": "1302975798304014336", "name": "Kate", "username": "MyelomaAmateur"}, {"id": "854692626015993857", "name": "Aaron Goodman - \u201cPapa Heme\u201d", "username": "AaronGoodman33"}, {"id": "1138405094", "name": "Dr. Jeffrey Zonder", "username": "Amyloid_Planet"}, {"id": "146995555", "name": "Rafael Fonseca MD \ud83c\uddfa\ud83c\uddf8\ud83c\udfdc\ud83c\uddf2\ud83c\uddfd", "username": "Rfonsi1"}, {"id": "1269642863924609025", "name": "Manni Mohyuddin", "username": "ManniMD1"}, {"id": "49103828", "name": "Fabio Pires", "username": "fabiopss"}, {"id": "983320272693616640", "name": "Eduardo F O Ribeiro", "username": "EduardoFlavioO1"}, {"id": "1144997352148787201", "name": "Amer Zeidan MBBS,MHS \u200f\u0639\u0627\u0645\u0631 \u0632\u064a\u062f\u0627\u0646", "username": "Dr_AmerZeidan"}, {"id": "191828708", "name": "Joaqu\u00edn D\u00edaz Schmidt", "username": "iHematologo"}, {"id": "258104765", "name": "Gabby Brauner Librizzi", "username": "Gabby_Brauner27"}, {"id": "1117857169528033280", "name": "Leonidas Platanias, MD", "username": "LeonidasPlatan1"}, {"id": "120125682", "name": "Dr. Luis Villela", "username": "hematologo"}, {"id": "28980128", "name": "Korey \ud83c\udf3b", "username": "kek608"}, {"id": "1068352638499020800", "name": "Rebecca Shatsky, MD", "username": "Dr_RShatsky"}, {"id": "1410748326908100631", "name": "PaulieC", "username": "pauliec80859931"}, {"id": "1005247473957457921", "name": "Mario L. Marques-Piubelli, MD", "username": "mario_pathology"}, {"id": "1039939970415218688", "name": "Andres Gomez", "username": "GomezDLeonMD"}, {"id": "2626263112", "name": "Mohamad Mohty", "username": "Mohty_EBMT"}, {"id": "1265795288427446273", "name": "@Hemepathguy", "username": "hemepathguy"}, {"id": "4466075238", "name": "Jordan Gauthier", "username": "drjgauthier"}, {"id": "2739065578", "name": "David Steensma, MD", "username": "DavidSteensma"}, {"id": "1325890564320092160", "name": "GELL_LATAM", "username": "GELL01433166"}, {"id": "24367340", "name": "JL Braga, CFA", "username": "jlbraga"}, {"id": "1316527561166458891", "name": "silvanacugliari", "username": "silcugliari"}, {"id": "300938004", "name": "Leonardo Trierveiler", "username": "lbtrier"}, {"id": "85214471", "name": "JUAN RANGEL MD", "username": "rajuan_27"}], "tweets": [{"conversation_id": "1600865250374361089", "source": "Twitter for iPad", "in_reply_to_user_id": "854692626015993857", "edit_history_tweet_ids": ["1600885571286548480"], "author_id": "3497730012", "referenced_tweets": [{"type": "replied_to", "id": "1600884532932071426"}], "id": "1600885571286548480", "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 28, "username": "chadinabhan", "id": "2212735524"}, {"start": 29, "end": 37, "username": "Nirvana", "id": "68412310"}, {"start": 38, "end": 48, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 49, "end": 55, "username": "sghmd", "id": "53395744"}, {"start": 56, "end": 68, "username": "DocsWhoRock", "id": "1266013486376726528"}, {"start": 69, "end": 78, "username": "montypal", "id": "24660850"}, {"start": 79, "end": 91, "username": "AleckAmalia", "id": "1331336294828437504"}, {"start": 92, "end": 104, "username": "DrRanaMcKay", "id": "1113559627809996801"}]}, "lang": "en", "created_at": "2022-12-08T16:10:37.000Z", "text": "@AaronGoodman33 @chadinabhan @Nirvana @ASkarbnik @sghmd @DocsWhoRock @montypal @AleckAmalia @DrRanaMcKay \u201cStrong words.\u201d\n\nSays the \ud83d\udc51 \ud83e\udd34 of them. \n\n\ud83d\ude02 \ud83e\udd1d \ud83e\udd2d\ud83d\udc4c"}, {"entities": {"annotations": [{"start": 113, "end": 121, "probability": 0.5787, "type": "Other", "normalized_text": "grey zone"}, {"start": 154, "end": 158, "probability": 0.5358, "type": "Other", "normalized_text": "DLBCL"}, {"start": 166, "end": 168, "probability": 0.4858, "type": "Other", "normalized_text": "cHL"}, {"start": 214, "end": 221, "probability": 0.623, "type": "Other", "normalized_text": "HGBL-NOS"}, {"start": 278, "end": 282, "probability": 0.6839, "type": "Other", "normalized_text": "RCHOP"}], "urls": [{"start": 48, "end": 71, "url": "https://t.co/ItDybSIgt0", "expanded_url": "https://ashpublications.org/blood/article-abstract/140/9/943/476913/Defining-and-treating-high-grade-B-cell-lymphoma?redirectedFrom=fulltext", "display_url": "ashpublications.org/blood/article-\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600681030557790208/bSSmiZpd?format=png&name=orig", "width": 520, "height": 685}, {"url": "https://pbs.twimg.com/news_img/1600681030557790208/bSSmiZpd?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Defining and treating high-grade B-cell lymphoma, NOS", "description": "Edited by Associate Editor Laurie Sehn, this 3-part Review Series covers rare, aggressive B-cell lymphomas. First, Olszewski et al discuss a recently-designated", "unwound_url": "https://ashpublications.org/blood/article-abstract/140/9/943/476913/Defining-and-treating-high-grade-B-cell-lymphoma?redirectedFrom=fulltext"}, {"start": 285, "end": 308, "url": "https://t.co/PClAO9jfuK", "expanded_url": "https://twitter.com/DrAEvens/status/1600862571162394624/photo/1", "display_url": "pic.twitter.com/PClAO9jfuK", "media_key": "3_1600862567634817025"}, {"start": 309, "end": 332, "url": "https://t.co/28dgiesTp9", "expanded_url": "https://twitter.com/guiperinimd/status/1600860652951568384", "display_url": "twitter.com/guiperinimd/st\u2026"}]}, "conversation_id": "1600862571162394624", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1600862571162394624"], "author_id": "719175246050410496", "referenced_tweets": [{"type": "quoted", "id": "1600860652951568384"}], "id": "1600862571162394624", "lang": "en", "created_at": "2022-12-08T14:39:14.000Z", "text": "Great question. We analyzed this in our review: https://t.co/ItDybSIgt0\n\nDefinite diagnostic challenges, like w/ grey zone lymphoma (aka intermediate b/t DLBCL &amp; cHL, etc).\n\nAnd even if definitive diagnosis of HGBL-NOS, unclear re: optimal Rx but know most pts do poorly w/ RCHOP. https://t.co/PClAO9jfuK https://t.co/28dgiesTp9"}, {"entities": {"hashtags": [{"start": 50, "end": 71, "tag": "HealthcareUnfiltered"}], "annotations": [{"start": 172, "end": 174, "probability": 0.3653, "type": "Other", "normalized_text": "MYC"}, {"start": 177, "end": 181, "probability": 0.4844, "type": "Other", "normalized_text": "DLBCL"}, {"start": 189, "end": 193, "probability": 0.531, "type": "Other", "normalized_text": "HGLBL"}, {"start": 245, "end": 247, "probability": 0.3392, "type": "Other", "normalized_text": "MYC"}, {"start": 254, "end": 258, "probability": 0.5088, "type": "Other", "normalized_text": "HGLBL"}, {"start": 294, "end": 295, "probability": 0.4715, "type": "Other", "normalized_text": "Tx"}], "mentions": [{"start": 0, "end": 10, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 11, "end": 20, "username": "DrAEvens", "id": "719175246050410496"}]}, "conversation_id": "1600685288430268416", "source": "Twitter for iPhone", "in_reply_to_user_id": "999010996034338818", "edit_history_tweet_ids": ["1600701514871283715"], "author_id": "2212735524", "referenced_tweets": [{"type": "replied_to", "id": "1600689149098356737"}], "id": "1600701514871283715", "lang": "en", "created_at": "2022-12-08T03:59:15.000Z", "text": "@ASkarbnik @DrAEvens Similar views do not help my #HealthcareUnfiltered podcast. Please disagree moving forward.\n\nBut indeed, the paper made me think of what would we do w MYC+ DLBCL &amp; HGLBL; (non-BL); I\u2019m not sure we know how best to treat MYC only HGLBL, but suspect most would intensify Tx."}, {"entities": {"hashtags": [{"start": 4, "end": 15, "tag": "MedTwitter"}], "annotations": [{"start": 5, "end": 14, "probability": 0.9418, "type": "Other", "normalized_text": "MedTwitter"}]}, "conversation_id": "1600845527331278848", "source": "Twitter for Android", "edit_history_tweet_ids": ["1600845527331278848"], "author_id": "75550503", "id": "1600845527331278848", "lang": "en", "created_at": "2022-12-08T13:31:30.000Z", "text": "Hey #MedTwitter !!\n\nBefore you belittle a speciality, remember, clinical medicine can't possibly survive w/o microbiology, pathology, biochemistry etc \ud83d\ude4f\ud83c\udffb"}, {"entities": {"annotations": [{"start": 57, "end": 59, "probability": 0.5132, "type": "Organization", "normalized_text": "MYC"}, {"start": 79, "end": 81, "probability": 0.7652, "type": "Organization", "normalized_text": "NHL"}, {"start": 92, "end": 96, "probability": 0.5451, "type": "Other", "normalized_text": "RCHOP"}], "mentions": [{"start": 21, "end": 35, "username": "BloodAdvances", "id": "732570175162179585"}, {"start": 107, "end": 117, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 118, "end": 130, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 131, "end": 146, "username": "AaronGoodman33", "id": "854692626015993857"}], "urls": [{"start": 149, "end": 172, "url": "https://t.co/5sw3fwWNsx", "expanded_url": "https://ashpublications.org/bloodadvances/article/6/22/5811/485287/Safety-and-efficacy-of-a-dose-dense-short-term?utm_source=&utm_medium=&utm_campaign=highlights_12_6_22&utm_source=sfmc&utm_medium=email&utm_campaign=BA+Highlights_12_6_22&utm_term=Link+Text", "display_url": "ashpublications.org/bloodadvances/\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1599788273773121537/xXGO_tPi?format=png&name=orig", "width": 520, "height": 685}, {"url": "https://pbs.twimg.com/news_img/1599788273773121537/xXGO_tPi?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma", "description": "Key Points. CARMEN regimen includes single doses of drugs delivered in 81 days (median), with good tolerability and lower risk of late toxicity.A 5-year OS of \u223c", "unwound_url": "https://ashpublications.org/bloodadvances/article/6/22/5811/485287/Safety-and-efficacy-of-a-dose-dense-short-term?utm_source=&utm_medium=&utm_campaign=highlights_12_6_22&utm_source=sfmc&utm_medium=email&utm_campaign=BA+Highlights_12_6_22&utm_term=Link+Text"}]}, "conversation_id": "1600467379158294528", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1600467379158294528"], "author_id": "2212735524", "id": "1600467379158294528", "lang": "en", "created_at": "2022-12-07T12:28:53.000Z", "text": "Interesting study in @BloodAdvances but are you treating MYC-only translocated NHL with non-RCHOP program?\n@ASkarbnik @GuiperiniMD @AaronGoodman33 \n\nhttps://t.co/5sw3fwWNsx+\u00bb&amp;utm_id=212692&amp;sfmc_id=19415589"}, {"entities": {"annotations": [{"start": 158, "end": 162, "probability": 0.5164, "type": "Place", "normalized_text": "Latin"}, {"start": 164, "end": 170, "probability": 0.4021, "type": "Place", "normalized_text": "America"}], "mentions": [{"start": 7, "end": 21, "username": "hosp_einstein", "id": "43108299"}, {"start": 191, "end": 200, "username": "Newsweek", "id": "2884771"}], "urls": [{"start": 250, "end": 273, "url": "https://t.co/CRbRaQCMQQ", "expanded_url": "https://www1.folha.uol.com.br/equilibrioesaude/2022/12/hospital-albert-einstein-anuncia-novo-centro-oncologico-de-r-12-bilhao.shtml", "display_url": "www1.folha.uol.com.br/equilibrioesau\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600205194343682073/AjGMmGFd?format=jpg&name=orig", "width": 2400, "height": 1600}, {"url": "https://pbs.twimg.com/news_img/1600205194343682073/AjGMmGFd?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Einstein anuncia novo centro oncol\u00f3gico de R$ 1,2 bilh\u00e3o - 06/12/2022 - Equil\u00edbrio e Sa\u00fade - Folha", "description": "Empreendimento ser\u00e1 erguido em bairro planejado na marginal Pinheiros e pretende figurar entre os dez melhores do mundo", "unwound_url": "https://www1.folha.uol.com.br/equilibrioesaude/2022/12/hospital-albert-einstein-anuncia-novo-centro-oncologico-de-r-12-bilhao.shtml"}]}, "conversation_id": "1600227764623134721", "source": "Twitter Web App", "edit_history_tweet_ids": ["1600227764623134721"], "author_id": "988990336784568320", "id": "1600227764623134721", "lang": "en", "created_at": "2022-12-06T20:36:44.000Z", "text": "Today, @hosp_einstein announced plans for a transformational cancer center, which will significantly advance our oncology department - currently ranked #1 in Latin America and #16 worldwide (@Newsweek). Estimated investment of 250 million dollars. \n\nhttps://t.co/CRbRaQCMQQ"}, {"entities": {"annotations": [{"start": 62, "end": 64, "probability": 0.8688, "type": "Other", "normalized_text": "GGM"}], "mentions": [{"start": 0, "end": 11, "username": "booksterpp", "id": "1276697665888272384"}]}, "conversation_id": "1600142501951651840", "source": "Twitter for iPhone", "in_reply_to_user_id": "1276697665888272384", "edit_history_tweet_ids": ["1600283244255014912"], "author_id": "3012914963", "referenced_tweets": [{"type": "replied_to", "id": "1600142501951651840"}], "id": "1600283244255014912", "lang": "pt", "created_at": "2022-12-07T00:17:11.000Z", "text": "@booksterpp Do amor e outros dem\u00f4nios \u00e9 meu livro favorito do GGM e quase ningu\u00e9m conhece."}, {"conversation_id": "1599065279786409985", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1600160019168649217"], "author_id": "354168091", "referenced_tweets": [{"type": "replied_to", "id": "1600100393232388096"}], "id": "1600160019168649217", "entities": {"mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 13, "end": 26, "username": "paulocruzphi", "id": "1913011345"}]}, "lang": "en", "created_at": "2022-12-06T16:07:32.000Z", "text": "@GuiperiniMD @paulocruzphi You keep saying this but maybe there is no conversation to be bad\u2026(ie you\u2019re alone in this one) \ud83d\ude09"}, {"entities": {"hashtags": [{"start": 0, "end": 12, "tag": "PeriniPicks"}, {"start": 23, "end": 29, "tag": "ASH22"}], "annotations": [{"start": 1, "end": 11, "probability": 0.4253, "type": "Other", "normalized_text": "PeriniPicks"}, {"start": 24, "end": 28, "probability": 0.4265, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 95, "end": 118, "url": "https://t.co/Bub7E7K9sR", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159001.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival", "description": "Program: Oral and Poster Abstracts Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Hodgkin lymphoma, Biological therapies, Antibody Therapy, Lymphomas, Diseases, Therapies, Lymphoid Malignancies Charlotte B Wagner, PharmD 1 *, Daniel A. Ermann, MD 2, Ken Boucher, PhD 3 *, Adrienne N. Nedved, PharmD 4 *, Ivana N. Micallef, MD 5, Sanjal H Desai, MBBS 6, Haris Hatic, DO 7, Gaurav Goyal, MD 8, Erin Zacholski, PharmD 9 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159001.html"}]}, "conversation_id": "1600149853220192258", "source": "Twitter Web App", "edit_history_tweet_ids": ["1600149853220192258"], "author_id": "1294745239656202240", "id": "1600149853220192258", "lang": "en", "created_at": "2022-12-06T15:27:09.000Z", "text": "#PeriniPicks No. 5 for #ASH22\nRWD confirms the benefit of BV consolidation after ASCT in HL. \n\nhttps://t.co/Bub7E7K9sR\n\nThe real important data in this abstract is that the benefit of BV remains in patients who needed dose-reductions or didnt get all 16 cycles."}, {"entities": {"annotations": [{"start": 18, "end": 24, "probability": 0.9779, "type": "Organization", "normalized_text": "Beatles"}, {"start": 118, "end": 127, "probability": 0.9395, "type": "Other", "normalized_text": "In my Life"}], "urls": [{"start": 141, "end": 164, "url": "https://t.co/CROtu4Egp7", "expanded_url": "https://twitter.com/rocknrollgarag1/status/1598812674984493056", "display_url": "twitter.com/rocknrollgarag\u2026"}]}, "conversation_id": "1599065279786409985", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1599065279786409985"], "author_id": "1913011345", "referenced_tweets": [{"type": "quoted", "id": "1598812674984493056"}], "id": "1599065279786409985", "lang": "pt", "created_at": "2022-12-03T15:37:26.000Z", "text": "O maior \u00e1lbum dos Beatles? Sim ou com certeza? (c\u00eas podem vir aqui nos coment\u00e1rios discordar de mim, n\u00e3o t\u00f4 nem a\u00ed). \u201cIn my Life\u201d \u00e9 del\u00edcia! https://t.co/CROtu4Egp7"}, {"entities": {"annotations": [{"start": 68, "end": 72, "probability": 0.5503, "type": "Other", "normalized_text": "Thurs"}], "mentions": [{"start": 0, "end": 10, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 11, "end": 26, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 27, "end": 39, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1599925397139099648", "source": "Twitter Web App", "in_reply_to_user_id": "999010996034338818", "edit_history_tweet_ids": ["1599947443327893504"], "author_id": "354168091", "referenced_tweets": [{"type": "replied_to", "id": "1599946249528291330"}], "id": "1599947443327893504", "lang": "en", "created_at": "2022-12-06T02:02:50.000Z", "text": "@ASkarbnik @AaronGoodman33 @GuiperiniMD Either of you guys there on Thurs?"}, {"entities": {"annotations": [{"start": 99, "end": 103, "probability": 0.7401, "type": "Other", "normalized_text": "RCHOP"}, {"start": 105, "end": 109, "probability": 0.6879, "type": "Other", "normalized_text": "RDHAP"}, {"start": 119, "end": 122, "probability": 0.519, "type": "Other", "normalized_text": "ASCT"}, {"start": 180, "end": 188, "probability": 0.5765, "type": "Other", "normalized_text": "ibrutinib"}, {"start": 241, "end": 243, "probability": 0.7009, "type": "Other", "normalized_text": "Ibr"}], "mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 28, "username": "matthew_mei", "id": "354168091"}]}, "conversation_id": "1599925397139099648", "source": "Twitter for iPhone", "in_reply_to_user_id": "854692626015993857", "edit_history_tweet_ids": ["1599935794260869120"], "author_id": "999010996034338818", "referenced_tweets": [{"type": "replied_to", "id": "1599930678090792960"}], "id": "1599935794260869120", "lang": "en", "created_at": "2022-12-06T01:16:33.000Z", "text": "@AaronGoodman33 @matthew_mei Well, wouldn\u2019t it be a similar conundrum then? Who\u2019s to say here that RCHOP/RDHAP without ASCT consolidation followed by R maintenance/observation and ibrutinib given only at relapse isn\u2019t similar in OS to using Ibr maintenance?"}, {"entities": {"annotations": [{"start": 23, "end": 25, "probability": 0.6593, "type": "Other", "normalized_text": "SMM"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 13, "end": 22, "username": "ManniMD1", "id": "1269642863924609025"}]}, "conversation_id": "1599057168103538690", "source": "Twitter for iPad", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1599374704380620800"], "author_id": "1455299166511538176", "referenced_tweets": [{"type": "replied_to", "id": "1599062642412306434"}], "id": "1599374704380620800", "lang": "en", "created_at": "2022-12-04T12:06:59.000Z", "text": "@GuiperiniMD @ManniMD1 SMM patient perspective here: it\u2019s true, pts not enrolled unwillingly. But \u201cknowing\u201d in this context (I.e., the info used to make decision, often at a time of great stress) is quite challenging for pts, and many rely on Dr advice. So do all pts really \u201cknow?\u201d"}, {"conversation_id": "1599212887939371008", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1599212887939371008"], "author_id": "4067920889", "id": "1599212887939371008", "entities": {"mentions": [{"start": 98, "end": 114, "username": "RockaDomicilioP", "id": "1569047557933830146"}, {"start": 115, "end": 126, "username": "marchenajr", "id": "24793170"}, {"start": 127, "end": 142, "username": "onorosaurosrex", "id": "64529857"}], "urls": [{"start": 143, "end": 166, "url": "https://t.co/vQhDS8RNls", "expanded_url": "https://twitter.com/i/web/status/1599212887939371008", "display_url": "twitter.com/i/web/status/1\u2026"}, {"start": 167, "end": 190, "url": "https://t.co/tPbdTaypbz", "expanded_url": "https://twitter.com/HemSandoval/status/1599212887939371008/video/1", "display_url": "pic.twitter.com/tPbdTaypbz", "media_key": "3_1599212062764417025"}]}, "lang": "ca", "created_at": "2022-12-04T01:23:59.000Z", "text": "Well, Jack white is mesmerizing. A freakin phenomenon. Jack White es un fen\u00f3meno. Toque perfecto! @RockaDomicilioP @marchenajr @onorosaurosrex https://t.co/vQhDS8RNls https://t.co/tPbdTaypbz"}, {"entities": {"annotations": [{"start": 0, "end": 6, "probability": 0.4995, "type": "Organization", "normalized_text": "Phoenix"}, {"start": 27, "end": 33, "probability": 0.3601, "type": "Organization", "normalized_text": "Phoenix"}], "mentions": [{"start": 62, "end": 78, "username": "RockaDomicilioP", "id": "1569047557933830146"}, {"start": 79, "end": 90, "username": "marchenajr", "id": "24793170"}], "urls": [{"start": 91, "end": 114, "url": "https://t.co/s2XClAbXMH", "expanded_url": "https://twitter.com/i/web/status/1599183740055351296", "display_url": "twitter.com/i/web/status/1\u2026"}, {"start": 115, "end": 138, "url": "https://t.co/Gi62soxFAC", "expanded_url": "https://twitter.com/HemSandoval/status/1599183740055351296/video/1", "display_url": "pic.twitter.com/Gi62soxFAC", "media_key": "7_1599182757590192130"}]}, "conversation_id": "1599183740055351296", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1599183740055351296"], "author_id": "4067920889", "id": "1599183740055351296", "lang": "es", "created_at": "2022-12-03T23:28:09.000Z", "text": "Phoenix en vivo es brutal! Phoenix live is brutal! Incre\u00edble. @RockaDomicilioP @marchenajr https://t.co/s2XClAbXMH https://t.co/Gi62soxFAC"}, {"entities": {"annotations": [{"start": 37, "end": 41, "probability": 0.9811, "type": "Person", "normalized_text": "Messi"}], "mentions": [{"start": 0, "end": 10, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 11, "end": 23, "username": "chadinabhan", "id": "2212735524"}, {"start": 24, "end": 36, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1598898857294802946", "source": "Twitter for iPhone", "in_reply_to_user_id": "999010996034338818", "edit_history_tweet_ids": ["1599173379541864448"], "author_id": "788922619005403137", "referenced_tweets": [{"type": "replied_to", "id": "1598898857294802946"}], "id": "1599173379541864448", "lang": "en", "created_at": "2022-12-03T22:46:59.000Z", "text": "@ASkarbnik @chadinabhan @GuiperiniMD Messi is looking unstoppable\u2026."}, {"entities": {"annotations": [{"start": 101, "end": 111, "probability": 0.9907, "type": "Place", "normalized_text": "New Orleans"}], "mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 28, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 29, "end": 41, "username": "chadinabhan", "id": "2212735524"}]}, "conversation_id": "1598826846082121728", "source": "Twitter for iPhone", "in_reply_to_user_id": "854692626015993857", "edit_history_tweet_ids": ["1599147358167580672"], "author_id": "999010996034338818", "referenced_tweets": [{"type": "replied_to", "id": "1599121358063304704"}], "id": "1599147358167580672", "lang": "en", "created_at": "2022-12-03T21:03:35.000Z", "text": "@AaronGoodman33 @GuiperiniMD @chadinabhan I think a piano or keyboard will be really easy to find in New Orleans!"}, {"entities": {"hashtags": [{"start": 49, "end": 54, "tag": "mmsm"}], "annotations": [{"start": 50, "end": 53, "probability": 0.5066, "type": "Other", "normalized_text": "mmsm"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 13, "end": 22, "username": "ManniMD1", "id": "1269642863924609025"}]}, "conversation_id": "1599057168103538690", "source": "Twitter Web App", "in_reply_to_user_id": "1302975798304014336", "edit_history_tweet_ids": ["1599122411927896064"], "author_id": "1302975798304014336", "referenced_tweets": [{"type": "replied_to", "id": "1599120646067589120"}], "id": "1599122411927896064", "lang": "en", "created_at": "2022-12-03T19:24:27.000Z", "text": "@GuiperiniMD @ManniMD1 That's part of why I love #mmsm; to see these debates and learn more about all the options and the studies and opinions that inform how drs treat. Sorry to ramble. 4/4"}, {"conversation_id": "1598826846082121728", "source": "Twitter for iPhone", "in_reply_to_user_id": "854692626015993857", "edit_history_tweet_ids": ["1599103860546555905"], "author_id": "2212735524", "referenced_tweets": [{"type": "replied_to", "id": "1599096718997737472"}], "id": "1599103860546555905", "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 28, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "lang": "en", "created_at": "2022-12-03T18:10:44.000Z", "text": "@AaronGoodman33 @GuiperiniMD Can I be there in case the exchange turns violent?"}, {"entities": {"annotations": [{"start": 53, "end": 56, "probability": 0.6216, "type": "Person", "normalized_text": "Dr P"}, {"start": 63, "end": 71, "probability": 0.8641, "type": "Other", "normalized_text": "Pearl Jam"}, {"start": 88, "end": 94, "probability": 0.8439, "type": "Organization", "normalized_text": "Nirvana"}], "mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 25, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1598826846082121728", "source": "Twitter for iPhone", "in_reply_to_user_id": "2212735524", "edit_history_tweet_ids": ["1599107232825999360"], "author_id": "854692626015993857", "referenced_tweets": [{"type": "replied_to", "id": "1599103860546555905"}], "id": "1599107232825999360", "lang": "en", "created_at": "2022-12-03T18:24:08.000Z", "text": "@chadinabhan @GuiperiniMD I am a peaceful man unless Dr P says Pearl Jam is superior to Nirvana."}, {"conversation_id": "1598826846082121728", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1599094082814775296"], "author_id": "854692626015993857", "referenced_tweets": [{"type": "replied_to", "id": "1598840007640305665"}], "id": "1599094082814775296", "entities": {"mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "lang": "en", "created_at": "2022-12-03T17:31:53.000Z", "text": "@GuiperiniMD I won\u2019t let this go.  You can mute me if it annoys you too much."}, {"entities": {"annotations": [{"start": 28, "end": 37, "probability": 0.8451, "type": "Other", "normalized_text": "Abbey Road"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1599020892016635905", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1599082188212838400"], "author_id": "1138405094", "referenced_tweets": [{"type": "replied_to", "id": "1599020892016635905"}], "id": "1599082188212838400", "lang": "en", "created_at": "2022-12-03T16:44:37.000Z", "text": "@GuiperiniMD Second side of Abbey Road. Do we really have to do this? \ud83d\ude09"}, {"conversation_id": "1598727392272748544", "source": "Twitter for iPhone", "in_reply_to_user_id": "26399236", "edit_history_tweet_ids": ["1599053785661575169"], "author_id": "146995555", "referenced_tweets": [{"type": "replied_to", "id": "1598920364205441024"}], "id": "1599053785661575169", "entities": {"mentions": [{"start": 0, "end": 16, "username": "RahulBanerjeeMD", "id": "26399236"}]}, "lang": "en", "created_at": "2022-12-03T14:51:46.000Z", "text": "@RahulBanerjeeMD We better check before assuming such code does not exist! \ud83e\udd23"}, {"conversation_id": "1599057168103538690", "source": "Twitter Web App", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1599063273055604736"], "author_id": "1269642863924609025", "referenced_tweets": [{"type": "replied_to", "id": "1599062642412306434"}], "id": "1599063273055604736", "entities": {"mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "lang": "en", "created_at": "2022-12-03T15:29:28.000Z", "text": "@GuiperiniMD Appreciate your input and sharing that. I don\u2019t think you are \u201ccorrecting\u201d something wrong I have said, but you context is helpful."}, {"entities": {"annotations": [{"start": 73, "end": 81, "probability": 0.65, "type": "Other", "normalized_text": "selinexor"}], "mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 22, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1599057168103538690", "source": "Twitter for iPhone", "in_reply_to_user_id": "1269642863924609025", "edit_history_tweet_ids": ["1599068075948929024"], "author_id": "854692626015993857", "referenced_tweets": [{"type": "replied_to", "id": "1599063273055604736"}], "id": "1599068075948929024", "lang": "en", "created_at": "2022-12-03T15:48:33.000Z", "text": "@ManniMD1 @GuiperiniMD I think prior to consent the doc should swallow a selinexor pill as they are presumably asymptomatic also.  A week later they can do the consent appropriately."}, {"entities": {"annotations": [{"start": 67, "end": 69, "probability": 0.75, "type": "Other", "normalized_text": "SMM"}, {"start": 192, "end": 193, "probability": 0.7738, "type": "Other", "normalized_text": "MM"}], "mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "conversation_id": "1599057168103538690", "source": "Twitter for Android", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1599063070243926018"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599062642412306434"}], "id": "1599063070243926018", "lang": "en", "created_at": "2022-12-03T15:28:39.000Z", "text": "@ManniMD1 Just a personal history.\nMy favourite aunt has high risk SMM. She asks me constantly if all she could do is wait for the disease to evolve. She is really smart and reads a lot about MM.\n\nShe Just cant handle being passive about it."}, {"conversation_id": "1599057168103538690", "source": "Twitter for Android", "in_reply_to_user_id": "1269642863924609025", "edit_history_tweet_ids": ["1599062642412306434"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1599057168103538690"}], "id": "1599062642412306434", "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "lang": "en", "created_at": "2022-12-03T15:26:57.000Z", "text": "@ManniMD1 Let me correct you.\n\n\"Should they be offered the opportunity of consenting to participate in a trial\".\n\nEnrollment is not a passive action. People are not treated without knowing the risks/possible benefits."}, {"entities": {"hashtags": [{"start": 269, "end": 274, "tag": "mmsm"}], "annotations": [{"start": 40, "end": 46, "probability": 0.7777, "type": "Other", "normalized_text": "myeloma"}, {"start": 270, "end": 273, "probability": 0.5998, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 275, "end": 298, "url": "https://t.co/F51Xc7ZuI3", "expanded_url": "https://twitter.com/HadidiSamer/status/1599042085541142528", "display_url": "twitter.com/HadidiSamer/st\u2026"}]}, "conversation_id": "1599057168103538690", "source": "Twitter Web App", "edit_history_tweet_ids": ["1599057168103538690"], "author_id": "1269642863924609025", "referenced_tweets": [{"type": "quoted", "id": "1599042085541142528"}], "id": "1599057168103538690", "lang": "en", "created_at": "2022-12-03T15:05:12.000Z", "text": "Those with intermediate risk smoldering myeloma according to 2/20/20 have a 18% chance of progression at 2 years.\n\nShould they be enrolled in a single arm small (n=15) trial of a drug with a much higher likelihood of severe toxicity (relative to risk of progression)?\n\n#mmsm https://t.co/F51Xc7ZuI3"}, {"entities": {"annotations": [{"start": 13, "end": 24, "probability": 0.8883, "type": "Other", "normalized_text": "Abbey Road B"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1599020892016635905", "source": "Twitter Web App", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1599045124427636737"], "author_id": "49103828", "referenced_tweets": [{"type": "replied_to", "id": "1599020892016635905"}], "id": "1599045124427636737", "lang": "en", "created_at": "2022-12-03T14:17:21.000Z", "text": "@GuiperiniMD Abbey Road B side"}, {"entities": {"annotations": [{"start": 44, "end": 53, "probability": 0.9747, "type": "Other", "normalized_text": "In My Life"}, {"start": 93, "end": 105, "probability": 0.7483, "type": "Other", "normalized_text": "Rubber Soul B"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}], "urls": [{"start": 113, "end": 136, "url": "https://t.co/Kfle0dNfHI", "expanded_url": "https://twitter.com/EduardoFlavioO1/status/1599042070999535616/photo/1", "display_url": "pic.twitter.com/Kfle0dNfHI", "media_key": "3_1599042063315640320"}]}, "conversation_id": "1599020892016635905", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1599042070999535616"], "author_id": "983320272693616640", "referenced_tweets": [{"type": "replied_to", "id": "1599021117838020608"}], "id": "1599042070999535616", "lang": "en", "created_at": "2022-12-03T14:05:13.000Z", "text": "@GuiperiniMD Maybe, you didn\u2019t realize that In My Life and all these others songs are on the Rubber Soul B-side. https://t.co/Kfle0dNfHI"}, {"entities": {"annotations": [{"start": 20, "end": 23, "probability": 0.5079, "type": "Other", "normalized_text": "Rush"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1599020892016635905", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1599025524323790849"], "author_id": "191828708", "referenced_tweets": [{"type": "replied_to", "id": "1599020892016635905"}], "id": "1599025524323790849", "lang": "en", "created_at": "2022-12-03T12:59:28.000Z", "text": "@GuiperiniMD 2112 - Rush"}, {"entities": {"annotations": [{"start": 66, "end": 80, "probability": 0.4935, "type": "Other", "normalized_text": "Magical Mistery"}, {"start": 128, "end": 137, "probability": 0.4947, "type": "Other", "normalized_text": "Penny Lane"}]}, "conversation_id": "1599020892016635905", "source": "Twitter for Android", "edit_history_tweet_ids": ["1599020892016635905"], "author_id": "1294745239656202240", "id": "1599020892016635905", "lang": "en", "created_at": "2022-12-03T12:41:03.000Z", "text": "What is your favourite B-side of a Record?\n\nI have no doubt it is Magical Mistery Tour:\nHello Goodbye\nStrawberry fields Forever\nPenny Lane\nBaby you're a rich Man\nAll you need is Love"}, {"entities": {"annotations": [{"start": 81, "end": 86, "probability": 0.9858, "type": "Person", "normalized_text": "Neymar"}]}, "conversation_id": "1598840613561958400", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1598840613561958400"], "author_id": "19608629", "id": "1598840613561958400", "lang": "pt", "created_at": "2022-12-03T00:44:41.000Z", "text": "\u00c9 uma pena que estejamos gastando dinheiro com col\u00e9gios e n\u00e3o em tratamentos pro Neymar melhorar logo."}, {"entities": {"annotations": [{"start": 48, "end": 54, "probability": 0.7259, "type": "Other", "normalized_text": "myeloma"}, {"start": 263, "end": 269, "probability": 0.6445, "type": "Other", "normalized_text": "myeloma"}]}, "conversation_id": "1598826846082121728", "source": "Twitter Web App", "edit_history_tweet_ids": ["1598826846082121728"], "author_id": "854692626015993857", "id": "1598826846082121728", "lang": "en", "created_at": "2022-12-02T23:49:59.000Z", "text": "I have been told it cruel to observe smoldering myeloma as patients will develop broken hips and backs.  I don't want this to happen!  \n\nShow me data treating prevents this (as opposed to PET+ bone lesion or Hb 10) and I will be glad to start treating smoldering myeloma."}, {"entities": {"hashtags": [{"start": 160, "end": 171, "tag": "MedTwitter"}], "annotations": [{"start": 161, "end": 170, "probability": 0.9117, "type": "Other", "normalized_text": "MedTwitter"}]}, "conversation_id": "1598720361964642304", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1598720361964642304"], "author_id": "258104765", "id": "1598720361964642304", "lang": "en", "created_at": "2022-12-02T16:46:51.000Z", "text": "Hey Attendings, if you were asked \u201cwhere do you see yourself in 10 years\u201d during residency interviews (like I\u2019ve been asked), how close are you to your answer? #MedTwitter"}, {"conversation_id": "1598445821682671616", "source": "Twitter Web App", "in_reply_to_user_id": "26399236", "edit_history_tweet_ids": ["1598532074880712704"], "author_id": "1117857169528033280", "referenced_tweets": [{"type": "replied_to", "id": "1598531591038709760"}], "id": "1598532074880712704", "entities": {"mentions": [{"start": 0, "end": 16, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 17, "end": 31, "username": "Dr_AmerZeidan", "id": "1144997352148787201"}]}, "lang": "en", "created_at": "2022-12-02T04:18:40.000Z", "text": "@RahulBanerjeeMD @Dr_AmerZeidan they have a good team.  But, lets be realistic, they will not go further."}, {"entities": {"annotations": [{"start": 16, "end": 27, "probability": 0.7942, "type": "Other", "normalized_text": "procarbazine"}, {"start": 48, "end": 52, "probability": 0.6303, "type": "Other", "normalized_text": "LATAM"}, {"start": 83, "end": 93, "probability": 0.9059, "type": "Other", "normalized_text": "dacarbazine"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1598658177087717376", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1598795246216814593"], "author_id": "4067920889", "referenced_tweets": [{"type": "replied_to", "id": "1598658177087717376"}], "id": "1598795246216814593", "lang": "en", "created_at": "2022-12-02T21:44:25.000Z", "text": "@GuiperiniMD Is procarbazine easy to procure in LATAM? Nowadays I guess we can use dacarbazine but just wondering. Its hard to get pro here.."}, {"entities": {"annotations": [{"start": 91, "end": 96, "probability": 0.9812, "type": "Place", "normalized_text": "Brazil"}], "mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 25, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 26, "end": 35, "username": "helops79", "id": "801866196127797251"}]}, "conversation_id": "1598728770642288640", "source": "Twitter for iPhone", "in_reply_to_user_id": "2212735524", "edit_history_tweet_ids": ["1598729579753082881"], "author_id": "999010996034338818", "referenced_tweets": [{"type": "replied_to", "id": "1598728770642288640"}], "id": "1598729579753082881", "lang": "en", "created_at": "2022-12-02T17:23:29.000Z", "text": "@chadinabhan @GuiperiniMD @helops79 They certainly will, showed it well today. But so will Brazil \ud83d\ude09"}, {"entities": {"annotations": [{"start": 60, "end": 62, "probability": 0.5728, "type": "Organization", "normalized_text": "ASH"}], "mentions": [{"start": 97, "end": 109, "username": "GuiperiniMD", "id": "1294745239656202240"}], "urls": [{"start": 111, "end": 134, "url": "https://t.co/6pa0xdTN5J", "expanded_url": "https://twitter.com/ASkarbnik/status/1598663070871687169/video/1", "display_url": "pic.twitter.com/6pa0xdTN5J", "media_key": "7_1598663038843879424"}]}, "conversation_id": "1598663070871687169", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1598663070871687169"], "author_id": "999010996034338818", "id": "1598663070871687169", "lang": "en", "created_at": "2022-12-02T12:59:12.000Z", "text": "Throwback to the Brazilian dueling pianos/drums takeover at ASH. Will we do it again this year?\n\u2066@GuiperiniMD\u2069 https://t.co/6pa0xdTN5J"}, {"conversation_id": "1598662643245424640", "source": "Twitter Web App", "edit_history_tweet_ids": ["1598662643245424640"], "author_id": "1497561976658141188", "referenced_tweets": [{"type": "quoted", "id": "1598661198051827712"}], "id": "1598662643245424640", "entities": {"mentions": [{"start": 4, "end": 13, "username": "sochihem", "id": "1504882776511713280"}, {"start": 14, "end": 23, "username": "GLinfoma", "id": "1388125179755307017"}, {"start": 24, "end": 36, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 37, "end": 48, "username": "Denicasuri", "id": "938692263181471744"}, {"start": 49, "end": 65, "username": "AstridPavlovsky", "id": "1091694525926567937"}, {"start": 66, "end": 77, "username": "hematologo", "id": "120125682"}, {"start": 78, "end": 92, "username": "SAHematologia", "id": "807626492"}, {"start": 93, "end": 105, "username": "hemato_maca", "id": "1543259507844943877"}, {"start": 106, "end": 116, "username": "Pilileonm", "id": "1552950526592970753"}], "urls": [{"start": 117, "end": 140, "url": "https://t.co/J84Y8njxVy", "expanded_url": "https://twitter.com/LymphomaEx/status/1598661198051827712", "display_url": "twitter.com/LymphomaEx/sta\u2026"}]}, "lang": "und", "created_at": "2022-12-02T12:57:30.000Z", "text": "cc: @sochihem @GLinfoma @GuiperiniMD @Denicasuri @AstridPavlovsky @hematologo @SAHematologia @hemato_maca @Pilileonm https://t.co/J84Y8njxVy"}, {"entities": {"hashtags": [{"start": 0, "end": 12, "tag": "PeriniPicks"}, {"start": 23, "end": 29, "tag": "ASH22"}], "annotations": [{"start": 1, "end": 11, "probability": 0.3816, "type": "Other", "normalized_text": "PeriniPicks"}, {"start": 24, "end": 28, "probability": 0.4323, "type": "Other", "normalized_text": "ASH22"}, {"start": 52, "end": 56, "probability": 0.4887, "type": "Other", "normalized_text": "RATHL"}, {"start": 150, "end": 153, "probability": 0.8236, "type": "Organization", "normalized_text": "LMIC"}, {"start": 168, "end": 176, "probability": 0.3347, "type": "Place", "normalized_text": "Bleomycin"}], "urls": [{"start": 122, "end": 145, "url": "https://t.co/nDl74hiBnt", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper162780.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Advanced Stage and Relapsed Hodgkin Lymphoma Hematology Disease Topics & Pathways: Research, clinical trials, Hodgkin lymphoma, Lymphomas, Clinical Research, Combination therapy, Diseases, Therapies, Lymphoid Malignancies Stefano Luminari, MD 1, Alexander Foss\u00e5, MD, PhD 2 *, Judith Trotman, FRACP 3, Daniel Molin 4 *, Francesco Annibale d'Amore, MD, DMSc 5, Gunilla Enblad,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper162780.html"}]}, "conversation_id": "1598658177087717376", "source": "Twitter Web App", "edit_history_tweet_ids": ["1598658177087717376"], "author_id": "1294745239656202240", "id": "1598658177087717376", "lang": "en", "created_at": "2022-12-02T12:39:45.000Z", "text": "#PeriniPicks No. 6 for #ASH22\n\nLong term f/u of the RATHL trial shows safety of both escalation and de-escalation in HL. \nhttps://t.co/nDl74hiBnt\n\nIn LMIC, shortage of Bleomycin is not uncommon, and being able of using only 2 cycles in 80% of patients helps us a lot."}, {"conversation_id": "1598108572206133248", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1598132337040330753"], "author_id": "120125682", "referenced_tweets": [{"type": "replied_to", "id": "1598108572206133248"}], "id": "1598132337040330753", "entities": {"mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "lang": "en", "created_at": "2022-12-01T01:50:15.000Z", "text": "@GuiperiniMD \ud83d\ude2c. Any experience recently?"}, {"entities": {"annotations": [{"start": 64, "end": 68, "probability": 0.9302, "type": "Other", "normalized_text": "Bible"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 13, "end": 25, "username": "Dr_RShatsky", "id": "1068352638499020800"}]}, "conversation_id": "1597812836633235457", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1598060931480977409"], "author_id": "28980128", "referenced_tweets": [{"type": "replied_to", "id": "1597923274088148994"}], "id": "1598060931480977409", "lang": "en", "created_at": "2022-11-30T21:06:31.000Z", "text": "@GuiperiniMD @Dr_RShatsky How is it not an accurate take on the Bible?"}, {"entities": {"hashtags": [{"start": 0, "end": 11, "tag": "OncTwitter"}, {"start": 176, "end": 181, "tag": "bcsm"}, {"start": 182, "end": 193, "tag": "MedTwitter"}], "annotations": [{"start": 1, "end": 10, "probability": 0.7265, "type": "Other", "normalized_text": "OncTwitter"}, {"start": 177, "end": 180, "probability": 0.5305, "type": "Other", "normalized_text": "bcsm"}, {"start": 183, "end": 192, "probability": 0.6302, "type": "Other", "normalized_text": "MedTwitter"}]}, "conversation_id": "1597812836633235457", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1597812836633235457"], "author_id": "1068352638499020800", "id": "1597812836633235457", "lang": "en", "created_at": "2022-11-30T04:40:40.000Z", "text": "#OncTwitter To both my oncologists and patient advocates. How should one respond when a patient tells you God will cure their [metastatic] cancer so they don\u2019t need treatment? #bcsm #MedTwitter"}, {"entities": {"annotations": [{"start": 170, "end": 181, "probability": 0.8621, "type": "Other", "normalized_text": "azathioprine"}, {"start": 206, "end": 220, "probability": 0.7597, "type": "Other", "normalized_text": "crohn's disease"}, {"start": 283, "end": 287, "probability": 0.8177, "type": "Other", "normalized_text": "HSTCL"}, {"start": 327, "end": 329, "probability": 0.6793, "type": "Other", "normalized_text": "IBD"}, {"start": 332, "end": 338, "probability": 0.7382, "type": "Other", "normalized_text": "Colitis"}, {"start": 343, "end": 347, "probability": 0.7805, "type": "Other", "normalized_text": "Crohn"}], "mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 29, "username": "GomezDLeonMD", "id": "1039939970415218688"}, {"start": 30, "end": 42, "username": "matthew_mei", "id": "354168091"}, {"start": 43, "end": 55, "username": "MediHumdani", "id": "1424156964"}, {"start": 56, "end": 69, "username": "Lymphoma_Doc", "id": "1080058020"}, {"start": 70, "end": 84, "username": "BijoyTelivala", "id": "964268621655695360"}, {"start": 85, "end": 96, "username": "WolverHeme", "id": "1504670558285406208"}, {"start": 97, "end": 109, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 110, "end": 121, "username": "hematologo", "id": "120125682"}, {"start": 122, "end": 134, "username": "AnnaSureda5", "id": "1330231762543370241"}, {"start": 135, "end": 146, "username": "graham74GC", "id": "2239893372"}]}, "conversation_id": "1597372199731486722", "source": "Twitter Web App", "in_reply_to_user_id": "854692626015993857", "edit_history_tweet_ids": ["1597399075925942272"], "author_id": "1410748326908100631", "referenced_tweets": [{"type": "replied_to", "id": "1597388215031595010"}], "id": "1597399075925942272", "lang": "en", "created_at": "2022-11-29T01:16:32.000Z", "text": "@AaronGoodman33 @GomezDLeonMD @matthew_mei @MediHumdani @Lymphoma_Doc @BijoyTelivala @WolverHeme @GuiperiniMD @hematologo @AnnaSureda5 @graham74GC My 22 yr old son takes azathioprine (since 2014) to manage crohn's disease, which probably makes him slightly susceptible to developing HSTCL.  What % of your patients suffer from IBD (Colitis or Crohn's)?  Thanks."}, {"entities": {"annotations": [{"start": 207, "end": 213, "probability": 0.6307, "type": "Other", "normalized_text": "P-GEMOX"}, {"start": 235, "end": 239, "probability": 0.705, "type": "Other", "normalized_text": "HSTCL"}], "mentions": [{"start": 0, "end": 15, "username": "ajperissinotti", "id": "1042599104227041281"}, {"start": 16, "end": 29, "username": "GomezDLeonMD", "id": "1039939970415218688"}, {"start": 30, "end": 45, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 46, "end": 58, "username": "MediHumdani", "id": "1424156964"}, {"start": 59, "end": 72, "username": "Lymphoma_Doc", "id": "1080058020"}, {"start": 73, "end": 87, "username": "BijoyTelivala", "id": "964268621655695360"}, {"start": 88, "end": 99, "username": "WolverHeme", "id": "1504670558285406208"}, {"start": 100, "end": 112, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 113, "end": 124, "username": "hematologo", "id": "120125682"}, {"start": 125, "end": 137, "username": "AnnaSureda5", "id": "1330231762543370241"}, {"start": 138, "end": 149, "username": "graham74GC", "id": "2239893372"}, {"start": 150, "end": 163, "username": "annabrown915", "id": "825884223794008064"}, {"start": 164, "end": 179, "username": "VictoriaNachar", "id": "326455500"}]}, "conversation_id": "1597372199731486722", "source": "Twitter for iPhone", "in_reply_to_user_id": "1042599104227041281", "edit_history_tweet_ids": ["1597623696805744640"], "author_id": "354168091", "referenced_tweets": [{"type": "replied_to", "id": "1597622463814594560"}], "id": "1597623696805744640", "lang": "en", "created_at": "2022-11-29T16:09:06.000Z", "text": "@ajperissinotti @GomezDLeonMD @AaronGoodman33 @MediHumdani @Lymphoma_Doc @BijoyTelivala @WolverHeme @GuiperiniMD @hematologo @AnnaSureda5 @graham74GC @annabrown915 @VictoriaNachar Interesting \u2014 v similar to P-GEMOX \u2014 does that work in HSTCL too?  Really nothing to lose in this setting\u2026"}, {"conversation_id": "1597558791977193473", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1597610510454759424"], "author_id": "1005247473957457921", "referenced_tweets": [{"type": "replied_to", "id": "1597558791977193473"}], "id": "1597610510454759424", "entities": {"mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "lang": "en", "created_at": "2022-11-29T15:16:42.000Z", "text": "@GuiperiniMD An important point to consider as well is the amount of kisses (1 to 3) depending of the region you are from! \ud83d\ude02\ud83d\ude02\ud83d\ude02"}, {"conversation_id": "1597211562355589120", "source": "Twitter Web App", "edit_history_tweet_ids": ["1597211562355589120"], "author_id": "1326389646", "id": "1597211562355589120", "entities": {"urls": [{"start": 112, "end": 135, "url": "https://t.co/0SHzPnY4FT", "expanded_url": "https://twitter.com/xruiztru/status/1597211562355589120/photo/1", "display_url": "pic.twitter.com/0SHzPnY4FT", "media_key": "3_1597211216371392514"}]}, "lang": "en", "created_at": "2022-11-28T12:51:25.000Z", "text": "To kiss or not to kiss?\n\nMap shows in red the countries where cheek kissing is a common way of greeting people. https://t.co/0SHzPnY4FT"}, {"entities": {"hashtags": [{"start": 0, "end": 12, "tag": "PeriniPicks"}, {"start": 23, "end": 29, "tag": "ASH22"}], "annotations": [{"start": 1, "end": 11, "probability": 0.4149, "type": "Other", "normalized_text": "PeriniPicks"}, {"start": 24, "end": 28, "probability": 0.4282, "type": "Other", "normalized_text": "ASH22"}, {"start": 103, "end": 106, "probability": 0.3509, "type": "Organization", "normalized_text": "ATLL"}], "mentions": [{"start": 180, "end": 193, "username": "GELL01433166", "id": "1325890564320092160"}, {"start": 194, "end": 205, "username": "Denicasuri", "id": "938692263181471744"}, {"start": 206, "end": 216, "username": "CamiPenaO", "id": "1205814890604175366"}, {"start": 217, "end": 228, "username": "FiadLorena", "id": "1091471892618399745"}], "urls": [{"start": 126, "end": 149, "url": "https://t.co/qjABXWca7t", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168334.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Rare Populations Hematology Disease Topics & Pathways: Research, adult, epidemiology, Lymphomas, elderly, Clinical Research, T Cell lymphoma, Diseases, real-world evidence, aggressive lymphoma, Lymphoid Malignancies, young adult , Study Population, Human Bryan Valcarcel, MD 1 *, Haruhiko Sano, MD 2 *, Hiroo Katsuya, MD, PhD 3 *, Atae Utsunomiya, MD 4, Maki Otsuka, MD 5 *, Masaharu Miyahara, MD 6", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168334.html"}]}, "conversation_id": "1597554949478813697", "source": "Twitter Web App", "edit_history_tweet_ids": ["1597554949478813697"], "author_id": "1294745239656202240", "id": "1597554949478813697", "lang": "en", "created_at": "2022-11-29T11:35:55.000Z", "text": "#PeriniPicks No. 7 for #ASH22 \n\nA huge international effort to evaluate how different populations with ATLL behave (n=837!): \nhttps://t.co/qjABXWca7t\n\nCongrats to all friends from @GELL01433166 @Denicasuri @CamiPenaO @FiadLorena and others! 1st oral presentation of many to come!"}, {"conversation_id": "1597372199731486722", "source": "Twitter for iPhone", "in_reply_to_user_id": "854692626015993857", "edit_history_tweet_ids": ["1597388580242194434"], "author_id": "120125682", "referenced_tweets": [{"type": "replied_to", "id": "1597388215031595010"}], "id": "1597388580242194434", "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 29, "username": "GomezDLeonMD", "id": "1039939970415218688"}, {"start": 30, "end": 42, "username": "matthew_mei", "id": "354168091"}, {"start": 43, "end": 55, "username": "MediHumdani", "id": "1424156964"}, {"start": 56, "end": 69, "username": "Lymphoma_Doc", "id": "1080058020"}, {"start": 70, "end": 84, "username": "BijoyTelivala", "id": "964268621655695360"}, {"start": 85, "end": 96, "username": "WolverHeme", "id": "1504670558285406208"}, {"start": 97, "end": 109, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 110, "end": 122, "username": "AnnaSureda5", "id": "1330231762543370241"}, {"start": 123, "end": 134, "username": "graham74GC", "id": "2239893372"}]}, "lang": "en", "created_at": "2022-11-29T00:34:50.000Z", "text": "@AaronGoodman33 @GomezDLeonMD @matthew_mei @MediHumdani @Lymphoma_Doc @BijoyTelivala @WolverHeme @GuiperiniMD @AnnaSureda5 @graham74GC Toxicity?"}, {"entities": {"hashtags": [{"start": 28, "end": 38, "tag": "CARTcells"}, {"start": 131, "end": 137, "tag": "lymsm"}, {"start": 138, "end": 146, "tag": "TcellRx"}], "annotations": [{"start": 29, "end": 37, "probability": 0.7951, "type": "Other", "normalized_text": "CARTcells"}, {"start": 132, "end": 136, "probability": 0.425, "type": "Other", "normalized_text": "lymsm"}, {"start": 139, "end": 145, "probability": 0.6632, "type": "Other", "normalized_text": "TcellRx"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1597223476771053570", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1597418538050125824"], "author_id": "1039939970415218688", "referenced_tweets": [{"type": "replied_to", "id": "1597223476771053570"}], "id": "1597418538050125824", "lang": "en", "created_at": "2022-11-29T02:33:52.000Z", "text": "@GuiperiniMD Could academic #CARTcells be cheaper than bispecs in the long run? What do you think of safety profile comparatively? #lymsm #TcellRx"}, {"entities": {"annotations": [{"start": 29, "end": 31, "probability": 0.4401, "type": "Other", "normalized_text": "AYA"}], "mentions": [{"start": 132, "end": 147, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 148, "end": 160, "username": "matthew_mei", "id": "354168091"}, {"start": 161, "end": 173, "username": "MediHumdani", "id": "1424156964"}, {"start": 174, "end": 187, "username": "Lymphoma_Doc", "id": "1080058020"}, {"start": 188, "end": 202, "username": "BijoyTelivala", "id": "964268621655695360"}, {"start": 203, "end": 214, "username": "WolverHeme", "id": "1504670558285406208"}, {"start": 215, "end": 227, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 228, "end": 239, "username": "hematologo", "id": "120125682"}, {"start": 240, "end": 252, "username": "AnnaSureda5", "id": "1330231762543370241"}, {"start": 253, "end": 264, "username": "graham74GC", "id": "2239893372"}]}, "conversation_id": "1597372199731486722", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1597372199731486722"], "author_id": "1039939970415218688", "id": "1597372199731486722", "lang": "en", "created_at": "2022-11-28T23:29:44.000Z", "text": "What\u2019s good for a fit person AYA w/refractory hepatosplenic T-cell lymphoma these days?\n\nPrior lines hyperCVAD and ICE elsewhere. \n\n@AaronGoodman33 @matthew_mei @MediHumdani @Lymphoma_Doc @BijoyTelivala @WolverHeme @GuiperiniMD @hematologo @AnnaSureda5 @graham74GC"}, {"entities": {"annotations": [{"start": 62, "end": 65, "probability": 0.8167, "type": "Organization", "normalized_text": "LMIC"}, {"start": 91, "end": 101, "probability": 0.5453, "type": "Organization", "normalized_text": "RIC alloHCT"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 184, "end": 195, "username": "hematologo", "id": "120125682"}, {"start": 196, "end": 208, "username": "iHematologo", "id": "191828708"}, {"start": 209, "end": 223, "username": "JulioChavezMD", "id": "3327918653"}, {"start": 224, "end": 234, "username": "ASkarbnik", "id": "999010996034338818"}]}, "conversation_id": "1597223476771053570", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1597273139368427520"], "author_id": "4067920889", "referenced_tweets": [{"type": "replied_to", "id": "1597223476771053570"}], "id": "1597273139368427520", "lang": "en", "created_at": "2022-11-28T16:56:06.000Z", "text": "@GuiperiniMD Agree. What to do next in high risk pts on CR at LMIC is Q. \ud83e\udd14. I would go for RIC alloHCT (when available) now that the donor pool has expanded with haplos. Any thoughts? @hematologo @iHematologo @JulioChavezMD @ASkarbnik ?"}, {"entities": {"hashtags": [{"start": 179, "end": 190, "tag": "MedTwitter"}], "annotations": [{"start": 180, "end": 189, "probability": 0.9419, "type": "Other", "normalized_text": "MedTwitter"}]}, "conversation_id": "1597253587293257729", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1597253587293257729"], "author_id": "24261916", "id": "1597253587293257729", "lang": "en", "created_at": "2022-11-28T15:38:25.000Z", "text": "Consider the possibility that your colleagues have thought about what you propose, and may have a good reason why they chose to do something different.\n\nAssume positive intent. \n #MedTwitter"}, {"entities": {"hashtags": [{"start": 0, "end": 12, "tag": "PeriniPicks"}, {"start": 23, "end": 29, "tag": "ASH22"}], "annotations": [{"start": 1, "end": 11, "probability": 0.504, "type": "Other", "normalized_text": "PeriniPicks"}, {"start": 24, "end": 28, "probability": 0.5448, "type": "Other", "normalized_text": "ASH22"}, {"start": 68, "end": 71, "probability": 0.7258, "type": "Organization", "normalized_text": "LMIC"}, {"start": 168, "end": 177, "probability": 0.8875, "type": "Other", "normalized_text": "Glofitamab"}], "urls": [{"start": 244, "end": 267, "url": "https://t.co/cFssiewpDj", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper157554.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Immune Based and Targeted Therapies in Relapsed/Refractory Large B-Cell Lymphoma Hematology Disease Topics & Pathways: Biological therapies, non-Hodgkin lymphoma, Lymphomas, Bispecific Antibody Therapy, B Cell lymphoma, Diseases, aggressive lymphoma, Therapies, Lymphoid Malignancies Martin Hutchings, MD, PhD 1 *, Carmelo Carlo-Stella, MD, PhD 2, Franck Morschhauser, MD, PhD 3 *, Emmanuel", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper157554.html"}]}, "conversation_id": "1597223476771053570", "source": "Twitter Web App", "edit_history_tweet_ids": ["1597223476771053570"], "author_id": "1294745239656202240", "id": "1597223476771053570", "lang": "en", "created_at": "2022-11-28T13:38:46.000Z", "text": "#PeriniPicks No. 8 for #ASH22 \nCarTs are going to be a challenge in LMIC, including prices, logistics, burocracy. \n\nAn option seems to be bispecifics. \nAnd the data on Glofitamab looks really good, with long responses after a finite therapy: \n\nhttps://t.co/cFssiewpDj"}, {"entities": {"hashtags": [{"start": 13, "end": 24, "tag": "hematology"}, {"start": 186, "end": 197, "tag": "MedTwitter"}], "annotations": [{"start": 76, "end": 78, "probability": 0.4571, "type": "Other", "normalized_text": "GCB"}, {"start": 99, "end": 102, "probability": 0.564, "type": "Other", "normalized_text": "BCL2"}, {"start": 120, "end": 122, "probability": 0.5784, "type": "Other", "normalized_text": "IPI"}, {"start": 187, "end": 196, "probability": 0.614, "type": "Other", "normalized_text": "MedTwitter"}]}, "conversation_id": "1597185209702977536", "source": "Twitter for Android", "edit_history_tweet_ids": ["1597185209702977536"], "author_id": "75550503", "id": "1597185209702977536", "lang": "en", "created_at": "2022-11-28T11:06:42.000Z", "text": "Question for #hematology fellows !!\n\n23,\u2642\ufe0f, stage 4b large B cell lymphoma, GCB type.\n\ud83d\udd38FISH: Myc + BCL2 rearranged\n\ud83d\udd38CNS IPI 3\n\ud83d\udd38LDH 2x ULN\n\nWhat is your approach w.r.t CNS prophylaxis??\n\n#MedTwitter"}, {"entities": {"annotations": [{"start": 51, "end": 56, "probability": 0.5558, "type": "Organization", "normalized_text": "Mexico"}], "mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 22, "username": "helops79", "id": "801866196127797251"}, {"start": 23, "end": 35, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 36, "end": 44, "username": "FIFAcom", "id": "140070953"}]}, "conversation_id": "1596580581072158723", "source": "Twitter for iPhone", "in_reply_to_user_id": "2212735524", "edit_history_tweet_ids": ["1596581244594262018"], "author_id": "999010996034338818", "referenced_tweets": [{"type": "replied_to", "id": "1596580581072158723"}], "id": "1596581244594262018", "lang": "en", "created_at": "2022-11-26T19:06:46.000Z", "text": "@chadinabhan @helops79 @GuiperiniMD @FIFAcom I\u2019m a Mexico fan since I was a little kid \ud83d\ude1c\ud83d\ude1c"}, {"entities": {"hashtags": [{"start": 40, "end": 46, "tag": "ASH22"}], "annotations": [{"start": 41, "end": 45, "probability": 0.6525, "type": "Other", "normalized_text": "ASH22"}], "mentions": [{"start": 75, "end": 83, "username": "TheIACH", "id": "1097392264903622658"}, {"start": 84, "end": 99, "username": "ASH_hematology", "id": "84072624"}, {"start": 100, "end": 111, "username": "Mohty_EBMT", "id": "2626263112"}], "urls": [{"start": 113, "end": 136, "url": "https://t.co/RRpdOwT8cY", "expanded_url": "https://twitter.com/AnnieLennox/status/1596189488317075456/video/1", "display_url": "pic.twitter.com/RRpdOwT8cY", "media_key": "7_1596189285597814786"}]}, "conversation_id": "1596547644502982658", "source": "Twitter for iPad", "edit_history_tweet_ids": ["1596547644502982658"], "author_id": "2626263112", "id": "1596547644502982658", "lang": "en", "created_at": "2022-11-26T16:53:15.000Z", "text": "Nothing can stop progress in hematology #ASH22 and this is evidence-based!\n@TheIACH @ASH_hematology @Mohty_EBMT \nhttps://t.co/RRpdOwT8cY"}, {"entities": {"annotations": [{"start": 19, "end": 29, "probability": 0.4793, "type": "Other", "normalized_text": "L - paisley"}, {"start": 91, "end": 105, "probability": 0.692, "type": "Other", "normalized_text": "Fender Mustangs"}], "urls": [{"start": 172, "end": 195, "url": "https://t.co/DixFWEcKh7", "expanded_url": "https://twitter.com/hemepathguy/status/1596218612817154048/photo/1", "display_url": "pic.twitter.com/DixFWEcKh7", "media_key": "3_1596218237363945472"}, {"start": 172, "end": 195, "url": "https://t.co/DixFWEcKh7", "expanded_url": "https://twitter.com/hemepathguy/status/1596218612817154048/photo/1", "display_url": "pic.twitter.com/DixFWEcKh7", "media_key": "3_1596218237460500480"}, {"start": 172, "end": 195, "url": "https://t.co/DixFWEcKh7", "expanded_url": "https://twitter.com/hemepathguy/status/1596218612817154048/photo/1", "display_url": "pic.twitter.com/DixFWEcKh7", "media_key": "3_1596218237573734400"}]}, "conversation_id": "1596218612817154048", "source": "Twitter Web App", "edit_history_tweet_ids": ["1596218612817154048"], "author_id": "1265795288427446273", "id": "1596218612817154048", "lang": "en", "created_at": "2022-11-25T19:05:48.000Z", "text": "Not just hemepath. L - paisley stratocaster UR - blue flower stratocaster LR - set of 1969 Fender Mustangs in competition burgandy, competition orange, and competition red https://t.co/DixFWEcKh7"}, {"conversation_id": "1596303487171981312", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1596303487171981312"], "author_id": "4466075238", "id": "1596303487171981312", "entities": {"urls": [{"start": 0, "end": 23, "url": "https://t.co/uQjYqFXb4a", "expanded_url": "https://twitter.com/drjgauthier/status/1596303487171981312/photo/1", "display_url": "pic.twitter.com/uQjYqFXb4a", "media_key": "3_1596303482386255873"}]}, "lang": "zxx", "created_at": "2022-11-26T00:43:03.000Z", "text": "https://t.co/uQjYqFXb4a"}, {"entities": {"hashtags": [{"start": 3, "end": 9, "tag": "ASH22"}, {"start": 246, "end": 252, "tag": "LATAM"}], "annotations": [{"start": 4, "end": 8, "probability": 0.5285, "type": "Other", "normalized_text": "ASH22"}, {"start": 33, "end": 36, "probability": 0.5387, "type": "Other", "normalized_text": "ASCT"}, {"start": 55, "end": 58, "probability": 0.6643, "type": "Other", "normalized_text": "PCNS"}, {"start": 179, "end": 181, "probability": 0.4589, "type": "Other", "normalized_text": "-HD"}, {"start": 191, "end": 195, "probability": 0.5778, "type": "Other", "normalized_text": "ARA-C"}, {"start": 210, "end": 212, "probability": 0.4545, "type": "Other", "normalized_text": "CMR"}, {"start": 215, "end": 222, "probability": 0.5982, "type": "Other", "normalized_text": "Thiotepa"}, {"start": 247, "end": 251, "probability": 0.3223, "type": "Other", "normalized_text": "LATAM"}, {"start": 272, "end": 277, "probability": 0.7664, "type": "Other", "normalized_text": "Matrix"}]}, "conversation_id": "1595874301865086976", "source": "Twitter for Android", "edit_history_tweet_ids": ["1595874301865086976"], "author_id": "1207849319770021888", "id": "1595874301865086976", "lang": "en", "created_at": "2022-11-24T20:17:38.000Z", "text": "In #ASH22 the question of HD and ASCT consolidation in PCNS lymphoma has been answered. But I have a more practical one about induction. 52 years old female received 2 cycles of R-HD MTX and ARA-C and achieved CMR. Thiotepa arrived at 3rd cycle (#LATAM). Do you switch to Matrix?"}, {"conversation_id": "1595431875761373184", "source": "Twitter for iPhone", "in_reply_to_user_id": "24261916", "edit_history_tweet_ids": ["1595439752941309952"], "author_id": "2739065578", "referenced_tweets": [{"type": "replied_to", "id": "1595431875761373184"}], "id": "1595439752941309952", "entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}]}, "lang": "en", "created_at": "2022-11-23T15:30:53.000Z", "text": "@VincentRK I don\u2019t understand the flame wars.  It\u2019s always possible to make a point without being rude or nasty."}, {"entities": {"hashtags": [{"start": 92, "end": 98, "tag": "ASH22"}], "annotations": [{"start": 0, "end": 11, "probability": 0.4118, "type": "Other", "normalized_text": "Blinatumomab"}, {"start": 54, "end": 61, "probability": 0.4758, "type": "Other", "normalized_text": "RCT ECOG"}], "urls": [{"start": 101, "end": 124, "url": "https://t.co/x6Wdp0Sv15", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Session23250.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "64th ASH Annual Meeting and Exposition: Late-Breaking Abstracts Session", "description": "Hall E (Ernest N. Morial Convention Center) David A. Garcia, MD, University of Washington and Olatoyosi Odenike, MD, University of Chicago No relevant conflicts of interest to declare. This highly anticipated session highlights the Joint Program Committees' selections of the highest-impact ab stracts, featuring substantive, novel, and groundbreaking data that were not available by the general abstract submission deadline and would otherwise not be presented at the ASH annual", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Session23250.html"}, {"start": 125, "end": 148, "url": "https://t.co/cBGVIGCe0X", "expanded_url": "https://twitter.com/GomezDLeonMD/status/1595222027648077824/photo/1", "display_url": "pic.twitter.com/cBGVIGCe0X", "media_key": "3_1595222022614704128"}]}, "conversation_id": "1595222027648077824", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1595222027648077824"], "author_id": "1039939970415218688", "id": "1595222027648077824", "lang": "en", "created_at": "2022-11-23T01:05:43.000Z", "text": "Blinatumomab consolidation plus ALL pediatric regimen RCT ECOG 1910\nKM curve looking good \ud83e\udd29 #ASH22 \n\nhttps://t.co/x6Wdp0Sv15 https://t.co/cBGVIGCe0X"}, {"entities": {"annotations": [{"start": 68, "end": 71, "probability": 0.6081, "type": "Other", "normalized_text": "News"}, {"start": 172, "end": 184, "probability": 0.4161, "type": "Place", "normalized_text": "Latin America"}], "mentions": [{"start": 52, "end": 67, "username": "ASH_hematology", "id": "84072624"}]}, "conversation_id": "1594906917423710209", "source": "Twitter Web App", "edit_history_tweet_ids": ["1594906917423710209"], "author_id": "1269642863924609025", "id": "1594906917423710209", "lang": "en", "created_at": "2022-11-22T04:13:35.000Z", "text": "One of the joys of reviewing abstracts/ writing for @ASH_hematology News Daily is to look across field of hematology and see great work.\n\nLoved seeing collab analysis from Latin America, hope for similar multinat collaborative groups from other areas (esp\ud83c\uddf5\ud83c\uddf0\ud83c\uddee\ud83c\uddf3!)\nSome examples \ud83d\udc47"}, {"entities": {"annotations": [{"start": 29, "end": 33, "probability": 0.3571, "type": "Other", "normalized_text": "Benda"}, {"start": 56, "end": 57, "probability": 0.9625, "type": "Place", "normalized_text": "US"}], "mentions": [{"start": 0, "end": 15, "username": "VexFlexPerplex", "id": "1532253631956803584"}, {"start": 16, "end": 28, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1594755753243459599", "source": "Twitter Web App", "in_reply_to_user_id": "1532253631956803584", "edit_history_tweet_ids": ["1595063193210351617"], "author_id": "354168091", "referenced_tweets": [{"type": "replied_to", "id": "1594774409625350145"}], "id": "1595063193210351617", "lang": "en", "created_at": "2022-11-22T14:34:34.000Z", "text": "@VexFlexPerplex @GuiperiniMD Benda slightly more in the US but not by much when I asked our pharmacy team"}, {"entities": {"annotations": [{"start": 32, "end": 35, "probability": 0.701, "type": "Organization", "normalized_text": "BCNU"}, {"start": 41, "end": 45, "probability": 0.3639, "type": "Place", "normalized_text": "Benda"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1594755753243459599", "source": "Twitter for Android", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1595003322062495744"], "author_id": "75550503", "referenced_tweets": [{"type": "replied_to", "id": "1594755753243459599"}], "id": "1595003322062495744", "lang": "en", "created_at": "2022-11-22T10:36:40.000Z", "text": "@GuiperiniMD In \ud83c\uddee\ud83c\uddf3, the cost of BCNU and Benda is almost the same !"}, {"entities": {"hashtags": [{"start": 249, "end": 260, "tag": "MedTwitter"}], "annotations": [{"start": 191, "end": 194, "probability": 0.7407, "type": "Organization", "normalized_text": "LMIC"}, {"start": 250, "end": 259, "probability": 0.8366, "type": "Other", "normalized_text": "MedTwitter"}], "mentions": [{"start": 130, "end": 144, "username": "DrNikitaMehra", "id": "228012790"}, {"start": 149, "end": 161, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 208, "end": 220, "username": "chadinabhan", "id": "2212735524"}]}, "conversation_id": "1594907680950218752", "source": "Twitter for Android", "edit_history_tweet_ids": ["1594907680950218752"], "author_id": "75550503", "id": "1594907680950218752", "lang": "en", "created_at": "2022-11-22T04:16:37.000Z", "text": "Spent an hour stuck in traffic \ud83d\udea6 but I'm not complaining, thanks to the Healthcare Unfiltered podcast  \ud83d\udc4d\ud83c\udffb \n\nSuper episode staring @DrNikitaMehra and @GuiperiniMD about practising oncology in LMIC.\n\nThank you @chadinabhan for doing what you do \ud83d\udc4d\ud83c\udffb\ud83d\udcaa\ud83c\udffc\n\n#MedTwitter"}, {"conversation_id": "1594398232012115970", "source": "Twitter for Android", "edit_history_tweet_ids": ["1594398232012115970"], "author_id": "23483816", "id": "1594398232012115970", "entities": {"urls": [{"start": 39, "end": 62, "url": "https://t.co/StvSn7J5X3", "expanded_url": "https://twitter.com/eliistender10/status/1594398232012115970/video/1", "display_url": "pic.twitter.com/StvSn7J5X3", "media_key": "7_1594398191599984643"}]}, "lang": "en", "created_at": "2022-11-20T18:32:15.000Z", "text": "The best werewolf transformation ever! https://t.co/StvSn7J5X3"}, {"entities": {"annotations": [{"start": 0, "end": 18, "probability": 0.5014, "type": "Other", "normalized_text": "Indian Hematologist"}, {"start": 104, "end": 110, "probability": 0.9187, "type": "Place", "normalized_text": "America"}]}, "conversation_id": "1594236682194518016", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1594236682194518016"], "author_id": "1336329089100046339", "id": "1594236682194518016", "lang": "en", "created_at": "2022-11-20T07:50:19.000Z", "text": "Indian Hematologist should not fall in trap of not doing early transplants advocated by few centre from America. There disease is different there treatment is different and ours is entirely different. Blindly copying will do more disservice to our Pts"}, {"conversation_id": "1593959032087367681", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1594070354095329280"], "author_id": "354168091", "referenced_tweets": [{"type": "replied_to", "id": "1593959032087367681"}], "id": "1594070354095329280", "entities": {"mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "lang": "en", "created_at": "2022-11-19T20:49:23.000Z", "text": "@GuiperiniMD Did a transplanter say that?  A little harsh IMO"}, {"entities": {"annotations": [{"start": 0, "end": 17, "probability": 0.8384, "type": "Person", "normalized_text": "Kris Kristofferson"}, {"start": 20, "end": 29, "probability": 0.9643, "type": "Person", "normalized_text": "Neil Young"}, {"start": 32, "end": 44, "probability": 0.959, "type": "Person", "normalized_text": "Willie Nelson"}, {"start": 158, "end": 167, "probability": 0.9205, "type": "Person", "normalized_text": "Nelson Ned"}], "urls": [{"start": 200, "end": 223, "url": "https://t.co/Hp4N3NVi7P", "expanded_url": "https://open.spotify.com/track/0tJqafmfyWDyUksQ0jNqCf?si=zX7fQe4PSZukSb3fhJlsLQ", "display_url": "open.spotify.com/track/0tJqafmf\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1593976354466316288/2z-FJ5_-?format=jpg&name=orig", "width": 640, "height": 640}, {"url": "https://pbs.twimg.com/news_img/1593976354466316288/2z-FJ5_-?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "N\u00e3o Tenho Culpa De Ser Triste", "description": "Nelson Ned \u00b7 Song \u00b7 1979", "unwound_url": "https://open.spotify.com/track/0tJqafmfyWDyUksQ0jNqCf?si=zX7fQe4PSZukSb3fhJlsLQ"}]}, "conversation_id": "1593976351568134144", "source": "Twitter for Android", "edit_history_tweet_ids": ["1593976351568134144"], "author_id": "1270700702608867330", "id": "1593976351568134144", "lang": "pt", "created_at": "2022-11-19T14:35:51.000Z", "text": "Kris Kristofferson? Neil Young? Willie Nelson? Ou\u00e7a essa m\u00fasica e diga se n\u00e3o poderia ter sido gravada por qualquer grande nome da m\u00fasica country. Mas era de Nelson Ned, composta e gravada em 1979...\nhttps://t.co/Hp4N3NVi7P"}, {"conversation_id": "1593688182855303171", "source": "Twitter for Android", "in_reply_to_user_id": "318757188", "edit_history_tweet_ids": ["1593733267257233412"], "author_id": "24367340", "referenced_tweets": [{"type": "replied_to", "id": "1593688182855303171"}], "id": "1593733267257233412", "entities": {"mentions": [{"start": 0, "end": 11, "username": "tecomedina", "id": "318757188"}]}, "lang": "und", "created_at": "2022-11-18T22:29:55.000Z", "text": "@tecomedina Zzzzzzzz"}, {"entities": {"hashtags": [{"start": 27, "end": 39, "tag": "PeriniPicks"}], "annotations": [{"start": 28, "end": 38, "probability": 0.3761, "type": "Other", "normalized_text": "PeriniPicks"}, {"start": 44, "end": 61, "probability": 0.5372, "type": "Other", "normalized_text": "Football World Cup"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1593619905412300804", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1593718527546253313"], "author_id": "1316527561166458891", "referenced_tweets": [{"type": "replied_to", "id": "1593619905412300804"}], "id": "1593718527546253313", "lang": "en", "created_at": "2022-11-18T21:31:21.000Z", "text": "@GuiperiniMD Are there any #PeriniPicks for Football World Cup?"}, {"entities": {"annotations": [{"start": 32, "end": 39, "probability": 0.5754, "type": "Other", "normalized_text": "Negronis"}, {"start": 80, "end": 83, "probability": 0.812, "type": "Other", "normalized_text": "BTKi"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1593609887745036294", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1593623066164109313"], "author_id": "999010996034338818", "referenced_tweets": [{"type": "replied_to", "id": "1593617857132331009"}], "id": "1593623066164109313", "lang": "en", "created_at": "2022-11-18T15:12:01.000Z", "text": "@GuiperiniMD Are you certain no Negronis were involved in the decision to count BTKi abstracts? \ud83d\ude1c"}, {"entities": {"annotations": [{"start": 81, "end": 83, "probability": 0.6836, "type": "Other", "normalized_text": "cHL"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "conversation_id": "1593619905412300804", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1593621230380367879"], "author_id": "300938004", "referenced_tweets": [{"type": "replied_to", "id": "1593619905412300804"}], "id": "1593621230380367879", "lang": "en", "created_at": "2022-11-18T15:04:44.000Z", "text": "@GuiperiniMD As a curious (anxious) ex-patient, is there something noteworthy on cHL?"}, {"entities": {"hashtags": [{"start": 0, "end": 12, "tag": "PeriniPicks"}], "annotations": [{"start": 119, "end": 123, "probability": 0.5876, "type": "Other", "normalized_text": "DLBCL"}, {"start": 190, "end": 194, "probability": 0.421, "type": "Other", "normalized_text": "DLBCL"}, {"start": 239, "end": 243, "probability": 0.5273, "type": "Other", "normalized_text": "DLBCL"}]}, "conversation_id": "1593619905412300804", "source": "Twitter Web App", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1593620336918122497"], "author_id": "1294745239656202240", "referenced_tweets": [{"type": "replied_to", "id": "1593619905412300804"}], "id": "1593620336918122497", "lang": "en", "created_at": "2022-11-18T15:01:11.000Z", "text": "#PeriniPicks No. 10\nAbst 1639\nHow Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?\n\nGreat work showing that control arms of ND DLBCL studies have similar outcomes of real-life DLBCL that fullfill IC/EC of these trials"}, {"entities": {"hashtags": [{"start": 64, "end": 76, "tag": "PeriniPicks"}, {"start": 81, "end": 87, "tag": "ASH22"}], "annotations": [{"start": 31, "end": 39, "probability": 0.7314, "type": "Organization", "normalized_text": "World Cup"}, {"start": 65, "end": 75, "probability": 0.6901, "type": "Other", "normalized_text": "PeriniPicks"}, {"start": 82, "end": 86, "probability": 0.7129, "type": "Other", "normalized_text": "ASH22"}, {"start": 89, "end": 96, "probability": 0.8305, "type": "Other", "normalized_text": "Lymphoma"}, {"start": 141, "end": 144, "probability": 0.7201, "type": "Organization", "normalized_text": "LMIC"}]}, "conversation_id": "1593619905412300804", "source": "Twitter Web App", "edit_history_tweet_ids": ["1593619905412300804"], "author_id": "1294745239656202240", "id": "1593619905412300804", "lang": "en", "created_at": "2022-11-18T14:59:28.000Z", "text": "Ok, let's start it because the World Cup is almost starting...\n\n#PeriniPicks for #ASH22! Lymphoma Abstracts focusing on impact of therapy in LMIC. No fancy drugs, no crazy stuff."}, {"conversation_id": "1593609887745036294", "source": "Twitter for iPhone", "in_reply_to_user_id": "1294745239656202240", "edit_history_tweet_ids": ["1593615932882042884"], "author_id": "999010996034338818", "referenced_tweets": [{"type": "replied_to", "id": "1593611960909701122"}], "id": "1593615932882042884", "entities": {"mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "lang": "en", "created_at": "2022-11-18T14:43:41.000Z", "text": "@GuiperiniMD It means you have a lot of free time to count abstracts, my friend!"}, {"entities": {"hashtags": [{"start": 16, "end": 22, "tag": "ASH22"}]}, "conversation_id": "1593609887745036294", "source": "Twitter for Android", "edit_history_tweet_ids": ["1593609887745036294"], "author_id": "1294745239656202240", "id": "1593609887745036294", "lang": "in", "created_at": "2022-11-18T14:19:39.000Z", "text": "BTKi matches in #ASH22 abstracts\n\nIbrutinib - 212 \ud83c\udfc6 \nAcalabrutinib - 75\nZanubrutinib - 45\nPirtobrutinib - 17\nNemtabrutinib - 3"}, {"entities": {"annotations": [{"start": 72, "end": 74, "probability": 0.6021, "type": "Other", "normalized_text": "MCL"}], "mentions": [{"start": 0, "end": 11, "username": "hematologo", "id": "120125682"}, {"start": 12, "end": 24, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 25, "end": 35, "username": "rajuan_27", "id": "85214471"}, {"start": 36, "end": 47, "username": "graham74GC", "id": "2239893372"}, {"start": 48, "end": 57, "username": "PerlaRcp", "id": "2308986078"}]}, "conversation_id": "1593352956665102336", "source": "Twitter for iPhone", "in_reply_to_user_id": "120125682", "edit_history_tweet_ids": ["1593408666832715776"], "author_id": "4067920889", "referenced_tweets": [{"type": "replied_to", "id": "1593407989242896385"}], "id": "1593408666832715776", "lang": "es", "created_at": "2022-11-18T01:00:04.000Z", "text": "@hematologo @GuiperiniMD @rajuan_27 @graham74GC @PerlaRcp Wow never for MCL. Interesante opci\u00f3n. \ud83e\udd14\ud83d\udc4d"}, {"entities": {"annotations": [{"start": 53, "end": 72, "probability": 0.7682, "type": "Other", "normalized_text": "Mantle Cell Lymphoma"}, {"start": 96, "end": 99, "probability": 0.639, "type": "Other", "normalized_text": "MIPI"}], "mentions": [{"start": 156, "end": 167, "username": "graham74GC", "id": "2239893372"}, {"start": 168, "end": 179, "username": "hematologo", "id": "120125682"}, {"start": 180, "end": 192, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 193, "end": 202, "username": "PerlaRcp", "id": "2308986078"}]}, "conversation_id": "1593352956665102336", "source": "Twitter for iPhone", "edit_history_tweet_ids": ["1593352956665102336"], "author_id": "85214471", "id": "1593352956665102336", "lang": "en", "created_at": "2022-11-17T21:18:42.000Z", "text": "What is your first-line treatment option for a 75 yo Mantle Cell Lymphoma patient, intermediate MIPI score, p53 unmutated, controlled comorbidities, ECOG 1\n@graham74GC @hematologo @GuiperiniMD @PerlaRcp"}]}, "errors": [{"value": "1599034589938601987", "detail": "Could not find tweet with referenced_tweets.id: [1599034589938601987].", "title": "Not Found Error", "resource_type": "tweet", "parameter": "referenced_tweets.id", "resource_id": "1599034589938601987", "type": "https://api.twitter.com/2/problems/resource-not-found"}, {"value": "1595907309125120000", "detail": "Could not find tweet with referenced_tweets.id: [1595907309125120000].", "title": "Not Found Error", "resource_type": "tweet", "parameter": "referenced_tweets.id", "resource_id": "1595907309125120000", "type": "https://api.twitter.com/2/problems/resource-not-found"}, {"resource_id": "4337973868", "parameter": "in_reply_to_user_id", "resource_type": "user", "section": "includes", "title": "Authorization Error", "value": "4337973868", "detail": "Sorry, you are not authorized to see the user with in_reply_to_user_id: [4337973868].", "type": "https://api.twitter.com/2/problems/not-authorized-for-resource"}, {"resource_id": "1595722478856314882", "parameter": "referenced_tweets.id", "resource_type": "tweet", "section": "includes", "title": "Authorization Error", "value": "1595722478856314882", "detail": "Sorry, you are not authorized to see the Tweet with referenced_tweets.id: [1595722478856314882].", "type": "https://api.twitter.com/2/problems/not-authorized-for-resource"}], "meta": {"result_count": 100, "newest_id": "1601232587623608320", "oldest_id": "1593358969396928513", "next_token": "7140dibdnow9c7btw424c4clsij8rnqh84578blhnul2r"}, "neighbors": ["2212735524", "999010996034338818", "854692626015993857", "120125682", "354168091"]}